Judith A Shizuru - Publications

Affiliations: 
Medicine Stanford University School of Medicine, Palo Alto, CA, United States 
Website:
https://biox.stanford.edu/people/judith-shizuru

257 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2023 Bader CS, Pavlova A, Lowsky R, Muffly L, Shiraz P, Arai S, Johnston LJ, Rezvani AR, Weng WK, Miklos DB, Frank MJ, Tamaresis JS, Agrawal V, Bharadwaj S, Sidana S, ... Shizuru JA, et al. Single Center Randomized Trial of T-reg graft alone versus T-reg graft Plus Tacrolimus for the Prevention of Acute GVHD. Blood Advances. PMID 38091578 DOI: 10.1182/bloodadvances.2023011625  0.396
2023 Magnani CF, Myburgh R, Brunn S, Chambovey M, Ponzo M, Volta L, Manfredi F, Pellegrino C, Pascolo S, Miskey C, Sandoval-Villegas N, Ivics Z, Shizuru JA, Neri D, Manz MG. Erratum: Anti-CD117 CAR T cells incorporating a safety switch eradicate human acute myeloid leukemia and hematopoietic stem cells. Molecular Therapy Oncolytics. 30: 150. PMID 37654971 DOI: 10.1016/j.omto.2023.08.002  0.384
2023 Magnani CF, Myburgh R, Brunn S, Chambovey M, Ponzo M, Volta L, Manfredi F, Pellegrino C, Pascolo S, Miskey C, Ivics Z, Shizuru JA, Neri D, Manz MG. Anti-CD117 CAR T cells incorporating a safety switch eradicate human acute myeloid leukemia and hematopoietic stem cells. Molecular Therapy Oncolytics. 30: 56-71. PMID 37583386 DOI: 10.1016/j.omto.2023.07.003  0.485
2022 Chang CA, Bhagchandani P, Poyser J, Velasco BJ, Zhao W, Kwon HS, Meyer E, Shizuru JA, Kim SK. Curative islet and hematopoietic cell transplantation in diabetic mice without toxic bone marrow conditioning. Cell Reports. 41: 111615. PMID 36351397 DOI: 10.1016/j.celrep.2022.111615  0.864
2022 Liang EC, Craig J, Torelli S, Cunanan K, Iglesias M, Arai S, Frank MJ, Johnston L, Lowsky R, Meyer EH, Miklos DB, Negrin R, Rezvani A, Shiraz P, Shizuru J, et al. Allogeneic Hematopoietic Cell Transplantation for Adult Acute Lymphoblastic Leukemia in the Modern Era. Transplantation and Cellular Therapy. PMID 35584783 DOI: 10.1016/j.jtct.2022.05.010  0.45
2022 Bankova AK, Caveney J, Yao B, Ramos TL, Bögeholz J, Heydari K, Diaz N, Jackson ML, Lowsky R, Brown JW, Johnston L, Rezvani AR, Frank MJ, Muffly L, Weng WK, ... ... Shizuru JA, et al. Real-world Experience of Cryopreserved Allogeneic Hematopoietic Grafts in the COVID-19 Pandemic: A Single Center Report. Transplantation and Cellular Therapy. PMID 35042013 DOI: 10.1016/j.jtct.2022.01.010  0.805
2021 Bankova AK, Pang W, Velasco BJ, Long-Boyle JR, Shizuru JA. 5-Azacytidine depletes hematopoietic stem cells and synergizes with an anti-CD117 antibody to augment donor engraftment in immunocompetent mice. Blood Advances. PMID 34448832 DOI: 10.1182/bloodadvances.2020003841  0.857
2021 Jensen KP, Hongo D, Ji X, Zheng P, Pawar RD, Wu HH, Busque S, Scandling JD, Shizuru JA, Lowsky R, Shori A, Dutt S, Waters J, Saraswathula A, Baker J, et al. Development of immunosuppressive myeloid cells to induce tolerance in solid organ and hematopoietic cell transplant recipients. Blood Advances. PMID 34432869 DOI: 10.1182/bloodadvances.2020003669  0.516
2021 Muffly L, Sundaram V, Chen C, Yurkiewicz I, Kuo E, Burnash S, Spiegel JY, Arai S, Frank MJ, Johnston LJ, Lowsky R, Meyer EH, Negrin RS, Rezvani AR, Sidana S, ... ... Shizuru JA, et al. Concordance of peripheral blood and bone marrow measurable residual disease in adult acute lymphoblastic leukemia. Blood Advances. 5: 3147-3151. PMID 34424318 DOI: 10.1182/bloodadvances.2021004234  0.33
2021 Spiegel JY, Patel S, Muffly L, Hossain NM, Oak J, Baird JH, Frank MJ, Shiraz P, Sahaf B, Craig J, Iglesias M, Younes S, Natkunam Y, Ozawa MG, Yang E, ... ... Shizuru J, et al. CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial. Nature Medicine. PMID 34312556 DOI: 10.1038/s41591-021-01436-0  0.3
2021 Lemieux C, Muffly LS, Iberri DJ, Craig JK, Johnston LJ, Lowsky R, Shiraz P, Rezvani AR, Frank MJ, Weng WK, Meyer E, Shizuru JA, Arai S, Liedtke M, Negrin RS, et al. Outcomes after delayed and second autologous stem cell transplant in patients with relapsed multiple myeloma. Bone Marrow Transplantation. PMID 34163014 DOI: 10.1038/s41409-021-01371-1  0.43
2021 Liang EC, Muffly LS, Shiraz P, Shizuru JA, Johnston L, Arai S, Frank MJ, Weng WK, Lowsky R, Rezvani A, Meyer EH, Negrin R, Miklos DB, Sidana S. Use of Backup Stem Cells for Stem Cell Boost and Second Transplant in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation. Transplantation and Cellular Therapy. PMID 33775587 DOI: 10.1016/j.jtct.2021.02.026  0.447
2020 Lemieux C, Johnston LJ, Lowsky R, Muffly LS, Craig JK, Shiraz P, Rezvani A, Frank MJ, Weng WK, Meyer E, Shizuru J, Arai S, Negrin R, Miklos DB, Sidana S. Outcomes with Autologous or Allogeneic Stem Cell Transplantation in Patients with Plasma Cell Leukemia in the Era of Novel Agents. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. PMID 32961371 DOI: 10.1016/J.Bbmt.2020.08.035  0.494
2020 Weng WK, Arai S, Rezvani A, Johnston L, Lowsky R, Miklos D, Shizuru J, Muffly L, Meyer E, Negrin RS, Wang E, Almazan T, Million L, Khodadoust M, Li S, et al. Nonmyeloablative allogeneic transplantation achieves clinical and molecular remission in cutaneous T-cell lymphoma. Blood Advances. 4: 4474-4482. PMID 32941647 DOI: 10.1182/Bloodadvances.2020001627  0.496
2020 Lemieux C, Muffly LS, Rezvani A, Lowsky R, Iberri DJ, Craig JK, Frank MJ, Johnston LJ, Liedtke M, Negrin R, Weng WK, Meyer E, Shizuru J, Shiraz P, Arai S, et al. Outcomes with autologous stem cell transplant vs. non-transplant therapy in patients 70 years and older with multiple myeloma. Bone Marrow Transplantation. PMID 32782351 DOI: 10.1038/S41409-020-01026-7  0.488
2020 Cooper JP, Storer BE, Granot N, Gyurkocza B, Sorror ML, Chauncey TR, Shizuru J, Franke GN, Maris MB, Boyer M, Bruno B, Sahebi F, Langston AA, Hari P, Agura ED, et al. Allogeneic hematopoietic cell transplantation with non-myeloablative conditioning for patients with hematologic malignancies: Improved outcomes over two decades. Haematologica. PMID 32499241 DOI: 10.3324/Haematol.2020.248187  0.518
2020 Busque S, Scandling JD, Lowsky R, Shizuru J, Jensen K, Waters J, Wu HH, Sheehan K, Shori A, Choi O, Pham T, Fernandez Vina MA, Hoppe R, Tamaresis J, Lavori P, et al. Mixed chimerism and acceptance of kidney transplants after immunosuppressive drug withdrawal. Science Translational Medicine. 12. PMID 31996467 DOI: 10.1126/Scitranslmed.Aax8863  0.552
2020 Tam EL, Iberri DJ, Liedtke M, Muffly LS, Shiraz P, Frank MJ, Lowsky R, Rezvani A, Negrin R, Meyer E, Arai S, Johnston LJ, Shizuru J, Weng W, Miklos DB, et al. Impact of proteasome inhibitor vs. IMiD maintenance therapy on outcomes of patients with high-risk multiple myeloma (HRMM). Journal of Clinical Oncology. 38: e20557-e20557. DOI: 10.1200/Jco.2020.38.15_Suppl.E20557  0.35
2020 Lemieux C, Muffly LS, Iberri DJ, Rezvani A, Lowsky R, Frank MJ, Craig JK, Liedtke M, Negrin R, Weng W, Meyer E, Johnston LJ, Shizuru J, Shiraz P, Arai S, et al. Autologous stem cell transplantation versus no transplant in patients above 70 with multiple myeloma. Journal of Clinical Oncology. 38: e20509-e20509. DOI: 10.1200/Jco.2020.38.15_Suppl.E20509  0.456
2020 Muffly L, Arai S, Johnston L, Lowsky R, Meyer EH, Miklos DB, Negrin RS, Rezvani A, Shiraz P, Shizuru JA, Sidana S, Weng W, Cunanan K. Allogeneic Hematopoietic Cell Transplantation for Adult Acute Lymphoblastic Leukemia: Significant Increase in Survival in the Post-Targeted Immunotherapy Era Biology of Blood and Marrow Transplantation. 26: S106. DOI: 10.1016/J.Bbmt.2019.12.611  0.411
2019 Shaw P, Shizuru J, Hoenig M, Veys P. Conditioning Perspectives for Primary Immunodeficiency Stem Cell Transplants. Frontiers in Pediatrics. 7: 434. PMID 31781522 DOI: 10.3389/Fped.2019.00434  0.589
2019 Shadman M, Maloney DG, Storer B, Sandmaier BM, Chauncey TR, Smedegaard Andersen N, Niederwieser D, Shizuru J, Bruno B, Pulsipher MA, Maziarz RT, Agura ED, Hari P, Langston AA, Maris MB, et al. Rituximab-based allogeneic transplant for chronic lymphocytic leukemia with comparison to historical experience. Bone Marrow Transplantation. PMID 31481800 DOI: 10.1038/S41409-019-0660-8  0.445
2019 Spinner MA, Kennedy VE, Tamaresis JS, Lavori PW, Arai S, Johnston LJ, Meyer EH, Miklos DB, Muffly LS, Negrin RS, Rezvani AR, Shizuru JA, Weng WK, Hoppe RT, Strober S, et al. Nonmyeloablative TLI-ATG conditioning for allogeneic transplantation: mature follow-up from a large single-center cohort. Blood Advances. 3: 2454-2464. PMID 31427277 DOI: 10.1182/Bloodadvances.2019000297  0.493
2019 Müller AM, Min D, Wernig G, Levy RB, Perez VL, Herretes S, Florek M, Burnett C, Weinberg K, Shizuru JA. Modeling chronic Graft-vs-Host disease in MHC-matched mouse strains: genetics, graft composition and tissue targets. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. PMID 31415899 DOI: 10.1016/J.Bbmt.2019.08.001  0.76
2019 George BM, Kao KS, Kwon HS, Velasco BJ, Poyser J, Chen A, Le AC, Chhabra A, Burnett CE, Cajuste D, Hoover M, Loh KM, Shizuru JA, Weissman IL. Antibody Conditioning Enables MHC-Mismatched Hematopoietic Stem Cell Transplants and Organ Graft Tolerance. Cell Stem Cell. PMID 31204177 DOI: 10.1016/J.Stem.2019.05.018  0.833
2019 Meyer EH, Laport G, Xie BJ, MacDonald K, Heydari K, Sahaf B, Tang SW, Baker J, Armstrong R, Tate K, Tadisco C, Arai S, Johnston L, Lowsky R, Muffly L, ... ... Shizuru J, et al. Transplantation of donor grafts with defined ratio of conventional and regulatory T cells in HLA-matched recipients. Jci Insight. 4. PMID 31092732 DOI: 10.1172/Jci.Insight.127244  0.609
2019 Pang WW, Czechowicz A, Logan AC, Bhardwaj R, Poyser J, Park CY, Weissman IL, Shizuru JA. Anti-CD117 antibody depletes normal and myelodysplastic syndrome human hematopoietic stem cells in xenografted mice. Blood. PMID 30745302 DOI: 10.1182/Blood-2018-06-858159  0.837
2019 Czechowicz A, Palchaudhuri R, Scheck A, Hu Y, Hoggatt J, Saez B, Pang WW, Mansour MK, Tate TA, Chan YY, Walck E, Wernig G, Shizuru JA, Winau F, Scadden DT, et al. Selective hematopoietic stem cell ablation using CD117-antibody-drug-conjugates enables safe and effective transplantation with immunity preservation. Nature Communications. 10: 617. PMID 30728354 DOI: 10.1038/S41467-018-08201-X  0.851
2019 Kwon HS, Logan AC, Chhabra A, Pang WW, Czechowicz A, Tate K, Le A, Poyser J, Hollis R, Kelly BV, Kohn DB, Weissman IL, Prohaska SS, Shizuru JA. Anti-human CD117 antibody-mediated bone marrow niche clearance in non-human primates and humanized NSG mice. Blood. PMID 30617195 DOI: 10.1182/Blood-2018-06-853879  0.799
2019 Sica RA, Spinner MA, Tamaresis JS, Advani RH, Johnston LJ, Lowsky R, Meyer EH, Miklos DB, Muffly LS, Rezvani AR, Shizuru JA, Weng W, Negrin RS, Arai S. Improved Outcomes for Relapsed/Refractory Classic Hodgkin Lymphoma Following Autologous Stem Cell Transplantation in the Era of Novel Agents Blood. 134: 2022-2022. DOI: 10.1182/Blood-2019-131532  0.356
2019 Agarwal R, Dvorak CC, Kwon H, Long-Boyle JR, Prohaska SS, Brown JW, Le A, Guttman-Klein A, Weissman IL, Cowan MJ, Logan AC, Weinberg KI, Parkman R, Roncarolo M, Shizuru JA. Non-Genotoxic Anti-CD117 Antibody Conditioning Results in Successful Hematopoietic Stem Cell Engraftment in Patients with Severe Combined Immunodeficiency Blood. 134: 800-800. DOI: 10.1182/Blood-2019-126239  0.853
2019 Gandhi A, Rezvani A, Lowsky R, Johnston L, Shizuru JA, Miklos DB, Arai S, Muffly L, Meyer EH, Negrin RS, Weng W. Dose-Intense BCNU/Melphalan Regimen Followed By Autologous Hematopoietic Cell Transplantation (AHCT) Results in Prolonged PFS in Myeloma Patients Biology of Blood and Marrow Transplantation. 25: S395-S396. DOI: 10.1016/J.Bbmt.2018.12.808  0.411
2019 Agarwal R, Dvorak CC, Prohaska S, Long-Boyle J, Kwon H, Brown J(M, Weinberg KI, Le A, Guttman-Klein A, Logan AC, Weissman IL, Digiusto D, Cowan MJ, Parkman R, Roncarolo MG, ... Shizuru JA, et al. Toxicity-Free Hematopoietic Stem Cell Engraftment Achieved with Anti-CD117 Monoclonal Antibody Conditioning Biology of Blood and Marrow Transplantation. 25: S92. DOI: 10.1016/J.Bbmt.2018.12.172  0.852
2018 Maffini E, Storer BE, Sandmaier BM, Bruno B, Sahebi F, Shizuru JA, Chauncey TR, Hari P, Lange T, Pulsipher MA, McSweeney PA, Holmberg L, Becker PS, Green DJ, Mielcarek M, et al. Long term follow-up of tandem autologous-allogeneic hematopoietic cell transplantation for multiple myeloma. Haematologica. PMID 30262560 DOI: 10.3324/Haematol.2018.200253  0.532
2018 Muffly L, Sheehan K, Armstrong R, Jensen K, Tate K, Rezvani AR, Miklos D, Arai S, Shizuru J, Johnston L, Meyer E, Weng WK, Laport GG, Negrin RS, Strober S, et al. Infusion of donor-derived CD8memory T cells for relapse following allogeneic hematopoietic cell transplantation. Blood Advances. 2: 681-690. PMID 29572391 DOI: 10.1182/Bloodadvances.2017012104  0.539
2018 Sockolosky JT, Trotta E, Parisi G, Picton L, Su LL, Le AC, Chhabra A, Silveria SL, George BM, King IC, Tiffany MR, Jude K, Sibener LV, Baker D, Shizuru JA, et al. Selective targeting of engineered T cells using orthogonal IL-2 cytokine-receptor complexes. Science (New York, N.Y.). 359: 1037-1042. PMID 29496879 DOI: 10.1126/Science.Aar3246  0.775
2018 Goldstone AB, Burnett CE, Cohen JE, Paulsen MJ, Eskandari A, Edwards BE, Ingason AB, Steele AN, Patel JB, MacArthur JW, Shizuru JA, Woo YJ. SDF 1-alpha Attenuates Myocardial Injury Without Altering the Direct Contribution of Circulating Cells. Journal of Cardiovascular Translational Research. PMID 29468554 DOI: 10.1007/S12265-017-9772-Y  0.702
2018 Scandling JD, Busque S, Lowsky R, Shizuru J, Shori A, Engleman E, Jensen K, Strober S. Macrochimerism and Clinical Transplant Tolerance. Human Immunology. PMID 29330112 DOI: 10.1016/J.Humimm.2018.01.002  0.548
2018 Spinner MA, Kennedy VE, Tamaresis JS, Lavori PW, Elder LV, Arai S, Johnston LJ, Meyer EH, Miklos DB, Muffly LS, Negrin RS, Rezvani AR, Shizuru JA, Weng W, Hoppe RT, et al. Nonmyeloablative Allogeneic Transplantation Using TLI-ATG Conditioning for Lymphoid and Myeloid Malignancies: Mature Follow-up from a Large, Single Institution Cohort Blood. 132: 4638-4638. DOI: 10.1182/Blood-2018-99-113597  0.449
2018 Spiegel JY, Sahaf B, Hossain N, Frank MJ, Claire G, Abramian M, Latchford T, Villa B, Cancilla J, Oak J, Natkunam Y, Long SR, Arai S, Johnston LJ, Lowsky R, ... ... Shizuru JA, et al. Elevated Axicabtagene Ciloleucel (CAR-19) Expansion By Immunophenotyping Is Associated with Toxicity in Diffuse Large B-Cell Lymphoma Blood. 132: 576-576. DOI: 10.1182/Blood-2018-99-113261  0.401
2018 Busque S, Scandling J, Lowsky R, Shizuru J, Jensen K, Shori A, Hoppe R, Engleman E, Meyer E, Strober S. Relationship Between Mixed Chimerism and Acceptance of HLA-matched and -Mismatched Kidney Transplants after Withdrawal of Immunosuppressive Drugs Transplantation. 102: S393. DOI: 10.1097/01.Tp.0000543161.65878.Ab  0.442
2018 Pang WW, Czechowicz A, Poyser J, Park CY, Weissman IL, Shizuru JA. Anti-Human CD117 Antibodies Mediate Clearance of Myelodysplastic Syndrome Hematopoietic Stem Cells and Facilitate Establishment of Normal Hematopoiesis in Transplantation Biology of Blood and Marrow Transplantation. 24: S230-S231. DOI: 10.1016/J.Bbmt.2017.12.211  0.84
2017 Spinner MA, Fernández-Viña M, Creary LE, Quinn O, Elder L, Arai S, Johnston LJ, Meyer EH, Miklos DB, Muffly LS, Negrin RS, Shizuru JA, Weng WK, Laport GG, Strober S, et al. HLA-mismatched unrelated donor transplantation using TLI-ATG conditioning has a low risk of GVHD and potent antitumor activity. Blood Advances. 1: 1347-1357. PMID 29296777 DOI: 10.1182/Bloodadvances.2017007716  0.47
2017 Veeraputhiran M, Yang L, Sundaram V, Arai S, Lowsky R, Miklos D, Meyer E, Muffly L, Negrin R, Rezvani A, Shizuru J, Weng WK, Johnston L. Validation of the Hematopoietic Cell Transplantation-Specific Comorbidity Index in Non-Myeloablative Allogeneic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. PMID 28668491 DOI: 10.1200/Jco.2016.34.15_Suppl.7046  0.422
2017 Cohen JE, Goldstone AB, Paulsen MJ, Shudo Y, Steele AN, Edwards BB, Patel JB, MacArthur JW, Hopkins MS, Burnett CE, Jaatinen KJ, Thakore AD, Farry JM, Truong VN, Bourdillon AT, ... ... Shizuru JA, et al. An innovative biologic system for photon-powered myocardium in the ischemic heart. Science Advances. 3: e1603078. PMID 28630913 DOI: 10.1126/Sciadv.1603078  0.573
2017 Pierini A, Nishikii H, Baker J, Kimura T, Kwon HS, Pan Y, Chen Y, Alvarez M, Strober W, Velardi A, Shizuru JA, Wu JY, Chiba S, Negrin RS. Foxp3(+) regulatory T cells maintain the bone marrow microenvironment for B cell lymphopoiesis. Nature Communications. 8: 15068. PMID 28485401 DOI: 10.1038/Ncomms15068  0.735
2017 Ho CC, Chhabra A, Starkl P, Schnorr PJ, Wilmes S, Moraga I, Kwon HS, Gaudenzio N, Sibilano R, Wehrman TS, Gakovic M, Sockolosky JT, Tiffany MR, Ring AM, Piehler J, ... ... Shizuru JA, et al. Decoupling the Functional Pleiotropy of Stem Cell Factor by Tuning c-Kit Signaling. Cell. 168: 1041-1052.e18. PMID 28283060 DOI: 10.1016/J.Cell.2017.02.011  0.8
2017 Spinner MA, Muffly LS, Arai S, Johnston L, Meyer EH, Miklos DB, Negrin RS, Rezvani AR, Shizuru JA, Weng W, Strober S, Lowsky R. Consolidative CD8+ Memory T-Cell Donor Lymphocyte Infusion Augments Donor Chimerism with a Low Risk of Gvhd Following Matched Related Donor Hematopoietic Cell Transplantation Blood. 130: 2003-2003. DOI: 10.1182/Blood.V130.Suppl_1.2003.2003  0.527
2017 Sorror ML, Sandmaier BM, Storer BE, Chauncey T, Shizuru JA, Franke G, Pulsipher MA, Maris MB, Bruno B, Andersen NS, Hari P, Langston AA, Sahebi F, Maziarz RT, Petersen FB, et al. Allogeneic Hematopoietic Cell Transplantation (HCT) in the Eighth Decade of Life: How Much Does Age Matter? Biology of Blood and Marrow Transplantation. 23: S98-S99. DOI: 10.1016/J.Bbmt.2017.01.040  0.509
2016 Müller AM, Florek M, Kohrt HE, Küpper NJ, Filatenkov A, Linderman JA, Hadeiba H, Negrin RS, Shizuru JA. Blood Stem Cell Activity Is Arrested by Th1-Mediated Injury Preventing Engraftment following Nonmyeloablative Conditioning. Journal of Immunology (Baltimore, Md. : 1950). 197: 4151-4162. PMID 27815446 DOI: 10.4049/Jimmunol.1500715  0.646
2016 Chhabra A, Ring AM, Weiskopf K, Schnorr PJ, Gordon S, Le AC, Kwon HS, Ring NG, Volkmer J, Ho PY, Tseng S, Weissman IL, Shizuru JA. Hematopoietic stem cell transplantation in immunocompetent hosts without radiation or chemotherapy. Science Translational Medicine. 8: 351ra105. PMID 27510901 DOI: 10.1126/Scitranslmed.Aae0501  0.843
2016 Neppalli AK, Shizuru J, Johnston LJ, Muffly LS, Weng W, Negrin R, Meyer E, Laport G, Lowsky R, Arai S, Miklos DB, Rezvani AR. Long-term outcomes of high-dose melphalan and carmustine followed by autologous hematopoietic cell transplantation for multiple myeloma. Journal of Clinical Oncology. 34: 8026-8026. DOI: 10.1200/Jco.2016.34.15_Suppl.8026  0.555
2016 Shadman M, Sorror ML, Sandmaier BM, Storer B, Chauncey TR, Andersen NS, Niederwieser D, Shizuru J, Bruno B, Pulsipher M, Maziarz RT, Agura ED, Hari P, Langston AA, Maris MB, et al. Adding peri-transplant rituximab to nonmyeloablative (NMA) conditioning before allogeneic hematopoietic cell transplantation (allo-HCT) to improve disease-related outcomes in patients with chronic lymphocytic leukemia (CLL): Phase II clinical trial. Journal of Clinical Oncology. 34: 7052-7052. DOI: 10.1200/Jco.2016.34.15_Suppl.7052  0.48
2016 Spinner MA, Fernandez Vina M, Elder L, Arai S, Johnston L, Meyer E, Miklos D, Muffly L, Negrin RS, Shizuru J, Weng W, Laport GG, Strober S, Lowsky R, Rezvani AR. Allogeneic Transplants from HLA-Mismatched Unrelated Donors Using Total Lymphoid Irradiation and Antithymocyte Globulin Conditioning Retain a Low Risk of Graft-Versus-Host Disease and Non-Relapse Mortality with at Least As Potent Anti-Tumor Activity As with Matched Unrelated Donors Blood. 128: 4669-4669. DOI: 10.1182/Blood.V128.22.4669.4669  0.516
2016 Muffly LS, Sheehan K, Armstrong R, Tate K, Tudisco C, Rezvani AR, Miklos D, Arai S, Shizuru J, Johnston L, Meyer E, Weng W, Laport GG, Negrin RS, Strober S, et al. Phase I Study of CD8 Memory T-Cell Donor Lymphocyte Infusion for Relapse of Hematologic Malignancies Following Matched Related Donor Allogeneic Hematopoietic Cell Transplantation Blood. 128: 4615-4615. DOI: 10.1182/Blood.V128.22.4615.4615  0.477
2016 Nishikii H, Pierini A, Yokoyama Y, Kimura T, Kwon H, Alvarez M, Baker J, Shizuru J, Wu J, Chiba S, Negrin RS. Foxp3+ regulatory T Cells Maintain Bone Marrow Microenvironment for B Cell Differentiation from Hematopoietic Stem Cells Blood. 128: 431-431. DOI: 10.1182/Blood.V128.22.431.431  0.738
2016 Susanne Mueller AM, Min D, Burnett C, Florek M, Weinberg KI, Shizuru JA. Allogeneic T Cells Disrupt Medullary Thymic Epithelial Cell Formation and Indirectly Lead to Chronic Graft-Vs-Host Disease Biology of Blood and Marrow Transplantation. 22: S45-S46. DOI: 10.1016/J.Exphem.2015.06.200  0.686
2015 Rezvani AR, Kanate AS, Efron B, Chhabra S, Kohrt HE, Shizuru JA, Laport GG, Miklos DB, Benjamin JE, Johnston LJ, Arai S, Weng WK, Negrin RS, Strober S, Lowsky R. Allogeneic hematopoietic cell transplantation after failed autologous transplant for lymphoma using TLI and anti-thymocyte globulin conditioning. Bone Marrow Transplantation. PMID 26146806 DOI: 10.1038/Bmt.2015.149  0.496
2015 Percival ME, Medeiros BC, Tian L, Robeson S, Laport GG, Johnston LJ, Shizuru JA, Miklos DB, Arai S, Weng WK, Negrin RS, Lowsky R. Allogeneic hematopoietic cell transplant for normal karyotype AML: indirect evidence of selection for adverse molecular profile. Bone Marrow Transplantation. 50: 1004-6. PMID 25893457 DOI: 10.1038/Bmt.2015.62  0.539
2015 Filatenkov A, Baker J, Mueller AM, Kenkel J, Ahn GO, Dutt S, Zhang N, Kohrt H, Jensen K, Dejbakhsh-Jones S, Shizuru JA, Negrin RN, Engleman EG, Strober S. Ablative Tumor Radiation Can Change the Tumor Immune Cell Microenvironment to Induce Durable Complete Remissions. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 25869387 DOI: 10.1158/1078-0432.Ccr-14-2824  0.309
2015 Scandling JD, Busque S, Shizuru JA, Lowsky R, Hoppe R, Dejbakhsh-Jones S, Jensen K, Shori A, Strober JA, Lavori P, Turnbull BB, Engleman EG, Strober S. Chimerism, graft survival, and withdrawal of immunosuppressive drugs in HLA matched and mismatched patients after living donor kidney and hematopoietic cell transplantation. American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons. 15: 695-704. PMID 25693475 DOI: 10.1111/Ajt.13091  0.536
2015 Narayan R, Benjamin J, Laport G, Tian L, Tate K, Elder L, Galvez L, Armstrong R, Sheehan K, Lowsky R, Arai S, Johnston L, Miklos D, Muffly LS, Rezvani AR, ... Shizuru J, et al. Donor-Derived CIK Cell Infusion As Consolidative Therapy after Non-Myeloablative Allogeneic Transplant in Patients with Myeloid Neoplasms Blood. 126: 3232-3232. DOI: 10.1182/Blood.V126.23.3232.3232  0.558
2015 Mueller AM, Min D, Burnett C, Florek M, Weinberg K, Shizuru JA. Allogeneic T cells disrupt medullary thymic epithelial cell formation and indirectly lead to chronic graft-vs-host disease Experimental Hematology. 43: S82. DOI: 10.1016/j.exphem.2015.06.200  0.328
2015 Chhabra A, Ring A, Weiskopf K, Schnorr PJ, Gordon S, Le AC, Kwon H, Guo N, Volkmer J, Ho PY, Tseng S, Weissman I, Shizuru J. HSC transplantation in an immunocompetent host without radiation or chemotherapy Experimental Hematology. 43: S57. DOI: 10.1016/J.Exphem.2015.06.101  0.795
2014 Filatenkov A, Baker J, Müller AM, Ahn GO, Kohrt H, Dutt S, Jensen K, Dejbakhsh-Jones S, Negrin RS, Shizuru JA, Engleman EG, Strober S. Treatment of 4T1 metastatic breast cancer with combined hypofractionated irradiation and autologous T-cell infusion. Radiation Research. 182: 163-9. PMID 24992165 DOI: 10.1667/Rr13471.1  0.363
2014 Medeiros BC, Tian L, Robenson S, Laport GG, Johnston LJ, Shizuru JA, Miklos DB, Arai S, Benjamin JE, Weng WK, Negrin RS, Lowsky R. European LeukemiaNet classification intermediate risk-1 cohort is associated with poor outcomes in adults with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation. Blood Cancer Journal. 4: e216. PMID 24879117 DOI: 10.1038/bcj.2014.35  0.354
2014 Benjamin J, Chhabra S, Kohrt HE, Lavori P, Laport GG, Arai S, Johnston L, Miklos DB, Shizuru JA, Weng WK, Negrin RS, Lowsky R. Total lymphoid irradiation-antithymocyte globulin conditioning and allogeneic transplantation for patients with myelodysplastic syndromes and myeloproliferative neoplasms. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. 20: 837-43. PMID 24607552 DOI: 10.1016/J.Bbmt.2014.02.023  0.475
2014 Müller AM, Poyser J, Küpper NJ, Burnett C, Ko RM, Kohrt HE, Florek M, Zhang P, Negrin RS, Shizuru JA. Donor hematopoiesis in mice following total lymphoid irradiation requires host T-regulatory cells for durable engraftment. Blood. 123: 2882-92. PMID 24591203 DOI: 10.1182/Blood-2013-10-530212  0.869
2014 Mueller AM, Poyser J, Kohrt HE, Shizuru JA. Conventional CD4+CD25- and Regulatory CDCD4+25+ t Cells Have Opposite Effects on Progenitor Cells and Hematopoietic Reconstitution Following Stem Cell Transplantation Blood. 124: 654-654. DOI: 10.1182/Blood.V124.21.654.654  0.861
2014 Weng W, Armstrong R, Arai S, Johnston L, Laport GG, Lowsky R, Miklos DB, Shizuru JA, Benjamin JE, Negrin RS, Reddy S, Million L, Hoppe RT, Kim YH. Non-Myeloablative Allogeneic Transplantation Resulting in Clinical and Molecular Remission with Low Non-Relapse Mortality (NRM) in Patients with Advanced Stage Mycosis Fungoides (MF) and Sézary Syndrome (SS) Blood. 124: 2544-2544. DOI: 10.1182/Blood.V124.21.2544.2544  0.495
2014 Chhabra A, Ring AM, Weiskopf K, Weissman IL, Shizuru JA. Successful Engraftment of Hematopoietic Stem Cells into Immunocompetent Recipients Using Only Anti-CD117 Antibody and CD47 Blockade As Conditioning Blood. 124: 2410-2410. DOI: 10.1182/Blood.V124.21.2410.2410  0.861
2014 Scandling J, Busque S, Shizuru J, Lowsky R, Dejbakhsh-Jones S, Jensen K, Shori A, Turnbull B, Engleman E, Strober S. Tolerance, Mixed Chimerism, and Graft Survival in HLA Matched and Mismatched Recipients of Kidney and Hematopoietic Cell Transplants. Transplantation. 98: 901. DOI: 10.1097/00007890-201407151-03081  0.543
2014 Wudhikarn K, Lavori P, Arai S, Johnston L, Laport GG, Lowsky R, Miklos DB, Shizuru JA, Hoppe RT, Benjamin J, Meyer E, Negrin R, Weng W. Outcome of Tandem Autologous/Allogeneic Hematopoietic Cell Transplantation in High-Risk Non Hodgkin's Lymphoma Patients: Stanford University Experience Biology of Blood and Marrow Transplantation. 20: S164. DOI: 10.1016/J.Bbmt.2013.12.262  0.483
2013 Rajasekaran N, Wang N, Hang Y, Macaubas C, Rinderknecht C, Beilhack GF, Shizuru JA, Mellins ED. B6.g7 mice reconstituted with BDC2·5 non-obese diabetic (BDC2·5NOD) stem cells do not develop autoimmune diabetes. Clinical and Experimental Immunology. 174: 27-37. PMID 23795893 DOI: 10.1111/Cei.12163  0.467
2013 Chen X, Wang Y, Li Q, Tsai S, Thomas A, Shizuru JA, Cao TM. Pathways analysis of differential gene expression induced by engrafting doses of total body irradiation for allogeneic bone marrow transplantation in mice. Immunogenetics. 65: 597-607. PMID 23703256 DOI: 10.1007/S00251-013-0710-0  0.479
2013 Wang Y, Chen X, Tsai S, Thomas A, Shizuru JA, Cao TM. Fine mapping of the Bmgr5 quantitative trait locus for allogeneic bone marrow engraftment in mice. Immunogenetics. 65: 585-96. PMID 23666360 DOI: 10.1007/S00251-013-0709-6  0.408
2013 Rajasekaran N, Wang N, Truong P, Rinderknecht C, Macaubas C, Beilhack GF, Shizuru JA, Mellins ED. Host-derived CD4+ T cells attenuate stem cell-mediated transfer of autoimmune arthritis in lethally irradiated C57BL/6.g7 mice. Arthritis and Rheumatism. 65: 681-92. PMID 23233229 DOI: 10.1002/Art.37800  0.474
2013 Benjamin J, Laport GG, Tate K, Galvez L, Armstrong R, Sheehan K, Arai S, Lowsky R, Johnston L, Miklos DB, Shizuru J, Weng W, Negrin R. Early Infusion Of Donor-Derived CIK Cells As Consolidative Immunotherapy Following Non-Myeloablative Allogeneic Transplantation: Safety and Feasibility Blood. 122: 899-899. DOI: 10.1182/Blood.V122.21.899.899  0.585
2013 Mueller AM, Florek M, Kuepper NJ, Poyser J, Shizuru JA. In Allogeneic Transplant Recipients Th17 Cells Originate From Donor Stem Cells and Reside In Target Organs of Chronic Graft-Versus-Host Disease Blood. 122: 5425-5425. DOI: 10.1182/Blood.V122.21.5425.5425  0.825
2013 Kanate AS, Efron B, Chhabra S, Kohrt H, Shizuru JA, Laport GG, Miklos DB, Benjamin J, Johnston L, Arai S, Weng W, Negrin R, Strober S, Lowsky R. Outcomes After Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation with Total Lymphoid Irradiation and Anti-Thymocyte Globulin in Lymphoid Malignancies After Failed Autologous Transplantation Biology of Blood and Marrow Transplantation. 19: S154-S155. DOI: 10.1016/J.Bbmt.2012.11.112  0.583
2013 Logan A, Sahaf B, Zhang B, Arai S, Carlton V, Zheng J, Moorhead M, Krampf MR, Jones CD, Waqar AN, Faham M, Shizuru JA, Zehnder JL, Miklos DB. Impaired B Cell Clonotype Diversification After Allogeneic Hematopoietic Cell Transplantation Predicts Graft-Versus-Host Disease Biology of Blood and Marrow Transplantation. 19: S148-S149. DOI: 10.1016/J.Bbmt.2012.11.100  0.544
2013 Benjamin J, Chhabra S, Kohrt H, Laport GG, Arai S, Johnston L, Miklos DB, Shizuru JA, Weng W, Negrin R, Lowsky R. TLI-ATG Conditioning and Allogeneic Transplantation for Patients with MDS and MPN Biology of Blood and Marrow Transplantation. 19: S113-S114. DOI: 10.1016/J.Bbmt.2012.11.035  0.501
2012 Logan AC, Weissman IL, Shizuru JA. The road to purified hematopoietic stem cell transplants is paved with antibodies. Current Opinion in Immunology. 24: 640-8. PMID 22939368 DOI: 10.1016/J.Coi.2012.08.002  0.709
2012 Arai S, Sahaf B, Narasimhan B, Chen GL, Jones CD, Lowsky R, Shizuru JA, Johnston LJ, Laport GG, Weng WK, Benjamin JE, Schaenman J, Brown J, Ramirez J, Zehnder JL, et al. Prophylactic rituximab after allogeneic transplantation decreases B-cell alloimmunity with low chronic GVHD incidence. Blood. 119: 6145-54. PMID 22563089 DOI: 10.1182/Blood-2011-12-395970  0.533
2012 Müller AM, Shashidhar S, Küpper NJ, Kohrt HE, Florek M, Negrin RS, Brown JM, Shizuru JA. Co-transplantation of pure blood stem cells with antigen-specific but not bulk T cells augments functional immunity. Proceedings of the National Academy of Sciences of the United States of America. 109: 5820-5. PMID 22440752 DOI: 10.1073/Pnas.1120237109  0.565
2012 Scandling JD, Busque S, Dejbakhsh-Jones S, Benike C, Sarwal M, Millan MT, Shizuru JA, Lowsky R, Engleman EG, Strober S. Tolerance and withdrawal of immunosuppressive drugs in patients given kidney and hematopoietic cell transplants. American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons. 12: 1133-45. PMID 22405058 DOI: 10.1111/J.1600-6143.2012.03992.X  0.589
2012 Müller AM, Kohrt HE, Cha S, Laport G, Klein J, Guardino AE, Johnston LJ, Stockerl-Goldstein KE, Hanania E, Juttner C, Blume KG, Negrin RS, Weissman IL, Shizuru JA. Long-term outcome of patients with metastatic breast cancer treated with high-dose chemotherapy and transplantation of purified autologous hematopoietic stem cells. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. 18: 125-33. PMID 21767515 DOI: 10.1016/J.Bbmt.2011.07.009  0.571
2012 Chen AI, Negrin RS, McMillan A, Shizuru JA, Johnston LJ, Lowsky R, Miklos DB, Arai S, Weng WK, Laport GG, Stockerl-Goldstein K. Tandem chemo-mobilization followed by high-dose melphalan and carmustine with single autologous hematopoietic cell transplantation for multiple myeloma. Bone Marrow Transplantation. 47: 516-21. PMID 21602899 DOI: 10.1038/bmt.2011.106  0.385
2012 Johnston L, Florek M, Armstrong R, McCune JS, Arai S, Brown J, Laport G, Lowsky R, Miklos D, Shizuru J, Sheehan K, Lavori P, Negrin R. Sirolimus and mycophenolate mofetil as GVHD prophylaxis in myeloablative, matched-related donor hematopoietic cell transplantation. Bone Marrow Transplantation. 47: 581-8. PMID 21552302 DOI: 10.1038/Bmt.2011.104  0.464
2012 Mueller AM, Shizuru JA, Kohrt HE. Achieving Selective Graft-Versus-Leukemia without Graft-Versus-Host Effects by WT1 Peptide Vaccination of Donors and Stringent Engineering of the Allo-Graft Blood. 120: 4108-4108. DOI: 10.1182/Blood.V120.21.4108.4108  0.498
2012 Logan AC, Czechowicz A, Kelley BV, Thway TM, Magana I, Krampf MR, Poyser J, Hollis RP, Kohn DB, Weissman IL, Shizuru JA. Anti-CD117 (c-Kit) Monoclonal Antibodies Deplete Human Hematopoietic Stem Cells and Facilitate Their Replacement in Humanized NOD/SCID/IL2Rγ−/− Mice: A Non-Toxic Conditioning Regimen for Allotransplantation Blood. 120: 4099-4099. DOI: 10.1182/Blood.V120.21.4099.4099  0.854
2012 Benjamin J, Chhabra S, Kohrt HE, Laport GG, Arai S, Johnston L, Miklos DB, Shizuru JA, Weng W, Negrin RS, Lowsky R. Non-Myeloablative Conditioning with Total Lymphoid Irradiation and ATG and Allogeneic Transplantation for Patients with Myelodysplastic Syndrome, Therapy-Related Myeloid Neoplasms, and Myeloproliferative Neoplasms. Blood. 120: 3087-3087. DOI: 10.1182/Blood.V120.21.3087.3087  0.475
2012 Mueller AM, Florek M, Kohrt HE, Shizuru JA. Immune Injury by Allogeneic CD4+ T Cells Leads to Host Hematopoietic Stem Cell Dormancy and Prevents Engraftment of Donor Cells. Blood. 120: 2366-2366. DOI: 10.1182/Blood.V120.21.2366.2366  0.638
2012 Scandling JD, Busque S, Dejbakhsh-Jones S, Benike C, Shori A, Shizuru J, Lowsky R, Engleman E, Strober S. A DecadeʼS Experience with Safety and Efficacy of Tolerance Induction in Clinical Kidney Transplantation Transplantation Journal. 94: 55. DOI: 10.1097/00007890-201211271-00100  0.405
2012 Mueller A, Poyser J, Kuepper N, Burnett C, Kohrt H, Florek M, Zhang P, Ko R, Shizuru J. Space and Tolerance Are Critical for Engraftment of Hematopoietic Allografts in Recipients Conditioned with Total Lymphoid Irradiation Plus ATG Biology of Blood and Marrow Transplantation. 18: S326-S327. DOI: 10.1016/J.Bbmt.2011.12.320  0.787
2012 Florek M, Sega E, Mueller A, Leveson-Gower D, Shizuru J, Negrin R. Infusion of Syngeneic Apoptotic Cells Prior to Bone Marrow Transplantation Decreases Tcell Proliferation and Increases Survival Biology of Blood and Marrow Transplantation. 18: S221. DOI: 10.1016/J.Bbmt.2011.12.054  0.413
2011 Scandling JD, Busque S, Shizuru JA, Engleman EG, Strober S. Induced immune tolerance for kidney transplantation. The New England Journal of Medicine. 365: 1359-60. PMID 21991976 DOI: 10.1056/Nejmc1107841  0.626
2011 Chen GL, Arai S, Flowers ME, Otani JM, Qiu J, Cheng EC, McMillan A, Johnston LJ, Shizuru JA, Miklos DB. A phase 1 study of imatinib for corticosteroid-dependent/refractory chronic graft-versus-host disease: response does not correlate with anti-PDGFRA antibodies. Blood. 118: 4070-8. PMID 21828142 DOI: 10.1182/Blood-2011-03-341693  0.355
2011 Laport GG, Sheehan K, Baker J, Armstrong R, Wong RM, Lowsky R, Johnston LJ, Shizuru JA, Miklos D, Arai S, Benjamin JE, Weng WK, Negrin RS. Adoptive immunotherapy with cytokine-induced killer cells for patients with relapsed hematologic malignancies after allogeneic hematopoietic cell transplantation. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. 17: 1679-87. PMID 21664472 DOI: 10.1016/J.Bbmt.2011.05.012  0.548
2011 Linderman JA, Shizuru JA. Rapid reconstitution of antibody responses following transplantation of purified allogeneic hematopoietic stem cells Journal of Immunology. 186: 4191-4199. PMID 21357265 DOI: 10.4049/Jimmunol.1003674  0.553
2011 Naik S, Wong R, Arai S, Brown J, Laport G, Lowsky R, Miklos D, Shizuru J, Blume K, Negrin R, Johnston L. Long-term outcomes in patients with high-risk myeloid malignancies following matched related donor hematopoietic cell transplantation with myeloablative conditioning of BU, etoposide and CY. Bone Marrow Transplantation. 46: 192-9. PMID 20498648 DOI: 10.1038/Bmt.2010.114  0.421
2011 Mueller AM, Kohrt HE, Shashidhar S, Florek M, Kuepper NJ, Brown J(M, Shizuru JA. Graft T Cells Retard Stem Cell Derived Lymphoid Organ Reconstitution and Immune Function After Allogeneic Transplantation, Blood. 118: 4030-4030. DOI: 10.1182/Blood.V118.21.4030.4030  0.597
2011 Florek M, Sega EI, Mueller AM, Leveson-Gower DB, Shizuru JA, Negrin RS. A Novel Model of Pre-Emptive ECP Treatment Shows Significant Reduction of Gvhd-Related Mortality In Mice, Blood. 118: 4025-4025. DOI: 10.1182/Blood.V118.21.4025.4025  0.528
2011 Ko R, Logronio K, Czechowicz A, Shizuru J. The Role of AMD3100 as a Preparative Regimen in Allogeneic Hematopoietic Cell Transplantation Biology of Blood and Marrow Transplantation. 17: S306-S307. DOI: 10.1016/J.Bbmt.2010.12.456  0.806
2011 Kuepper N, Mueller A, Tran P, Shizuru J. Liver Immunity Has Protective Functions After Hematopoietic Cell Transplantation But Can Contribute to Rejection of the Graft Biology of Blood and Marrow Transplantation. 17: S233. DOI: 10.1016/j.bbmt.2010.12.243  0.426
2011 Mueller A, Florek M, Hadeiba H, Shizuru J. Donor CD4 Cells Induce Host Microenvironment Inflammation After Nonmyeloablative Hematopoietic Cell Transplantation Which Suppresses Hematopoiesis and Contributes to Graft Rejection Biology of Blood and Marrow Transplantation. 17: S232. DOI: 10.1016/J.Bbmt.2010.12.240  0.529
2011 Mueller A, Kohrt H, Laport G, Negrin R, Cha S, Weissman I, Shizuru J. Long-Term Follow-Up of Metastatic Breast Cancer Patients Receiving Highly Purified Autologous CD34+Thy-1+ Hematopoietic Stem Cells After High-Dose Chemotherapy Biology of Blood and Marrow Transplantation. 17: S198. DOI: 10.1016/j.bbmt.2010.12.144  0.474
2010 Müller AMS, Linderman JA, Florek M, Miklos D, Shizuru JA. Allogeneic T cells impair engraftment and hematopoiesis after stem cell transplantation Proceedings of the National Academy of Sciences of the United States of America. 107: 14721-14726. PMID 20679222 DOI: 10.1073/Pnas.1009220107  0.591
2010 Shustov AR, Gooley TA, Sandmaier BM, Shizuru J, Sorror ML, Sahebi F, McSweeney P, Niederwieser D, Bruno B, Storb R, Maloney DG. Allogeneic haematopoietic cell transplantation after nonmyeloablative conditioning in patients with T-cell and natural killer-cell lymphomas. British Journal of Haematology. 150: 170-8. PMID 20507311 DOI: 10.1111/J.1365-2141.2010.08210.X  0.504
2010 Gyurkocza B, Storb R, Storer BE, Chauncey TR, Lange T, Shizuru JA, Langston AA, Pulsipher MA, Bredeson CN, Maziarz RT, Bruno B, Petersen FB, Maris MB, Agura E, Yeager A, et al. Nonmyeloablative allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 28: 2859-67. PMID 20439626 DOI: 10.1200/Jco.2009.27.1460  0.5
2010 Arai S, Letsinger R, Wong RM, Johnston LJ, Laport GG, Lowsky R, Miklos DB, Shizuru JA, Weng WK, Lavori PW, Blume KG, Negrin RS, Horning SJ. Phase I/II trial of GN-BVC, a gemcitabine and vinorelbine-containing conditioning regimen for autologous hematopoietic cell transplantation in recurrent and refractory hodgkin lymphoma. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. 16: 1145-54. PMID 20197102 DOI: 10.1016/J.Bbmt.2010.02.022  0.443
2010 Shizuru JA, Bhattacharya D, Cavazzana-Calvo M. The biology of allogeneic hematopoietic cell resistance. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. 16: S2-7. PMID 19913629 DOI: 10.1016/J.Bbmt.2009.11.005  0.696
2010 Mueller AM, Florek M, Hadeiba H, Shizuru JA. Interactions Between Donor CD4 Cells and Residual Host Cells After Nonmyeloablative Hematopoietic Stem Cell Transplantation Suppress Hematopoiesis and Lead to Graft Rejection Blood. 116: 75-75. DOI: 10.1182/Blood.V116.21.75.75  0.623
2010 Mueller AM, Shashidhar S, Brown J, Shizuru JA. Adoptively Transferred Mature T Cells Exhibit Diminished Reactivity to Murine Cytomegalovirus Compared to Nascent Donor T Cells and Impair Functional Immune Recovery After Allogeneic Hematopoietic Cell Transplantation. Blood. 116: 3732-3732. DOI: 10.1182/Blood.V116.21.3732.3732  0.573
2010 Chen GL, Arai S, Flowers ME, Otani JM, Coram M, McMillan A, Shizuru JA, Johnston L, Miklos D. Chronic Graft-Versus-Host Disease Responds to Imatinib and Pre Transplant/Donor Anti-PDGFRA Antibodies Predict for Chronic Graft-Versus-Host Disease Development Blood. 116: 2320-2320. DOI: 10.1182/Blood.V116.21.2320.2320  0.45
2010 Strober S, Busque S, Dejbakhsh-Jones S, Benike C, Li L, Shizuru J, Lowsky R, Engleman E, Sarwal M, Scandling JD. INDUCING TOLERANCE IN CLINICAL KIDNEY TRANSPLANTATION Transplantation Journal. 90: 323. DOI: 10.1097/00007890-201007272-00609  0.454
2010 Thakar M, Storer B, Storb R, Shizuru J, Niederwieser D, Pulsipher M, Sahebi F, Sorror M, Chen Y, Georges G, Maloney D, Woolfrey A, Sandmaier B. Treatment Of Pediatric High-Risk Malignancies Using Non-Myeloablative (NM) Hematopoietic Cell Transplantation (HCT): A Multi-Institutional Experience Biology of Blood and Marrow Transplantation. 16: S246-S247. DOI: 10.1016/j.bbmt.2009.12.277  0.378
2010 Mueller A, Tran P, Shizuru J. The Liver Maintains Strong Populations Of Innate Immune Cells That Contribute To Host Protection After Allogeneic Hematopoietic Cell Transplantation Biology of Blood and Marrow Transplantation. 16: S224. DOI: 10.1016/j.bbmt.2009.12.213  0.413
2010 Mueller A, Florek M, Shizuru J. Engraftment Failure After Nonmyeloablative Hematopoietic Stem Cell Transplantation: Donor CD4 Cells Interfere With Residual Host Cells And Can Trigger Graft Rejection Biology of Blood and Marrow Transplantation. 16: S162-S163. DOI: 10.1016/j.bbmt.2009.12.034  0.544
2009 Naik SG, Negrin R, Laport G, Miklos D, Shizuru J, Arai S, Blume K, Wong R, Lowsky R, Johnston L. Long-term outcomes of high-dose therapy using busulfan, etoposide, and cyclophosphamide followed by allogeneic hematopoietic cell transplantation for patients with high-risk or advanced stages of myeloid malignancies. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 7033. PMID 27961395 DOI: 10.1200/jco.2009.27.15_suppl.7033  0.316
2009 Filatenkov A, Müller AM, Tseng WW, Dejbakhsh-Jones S, Winer D, Luong R, Shizuru JA, Engleman EG, Strober S. Ineffective vaccination against solid tumors can be enhanced by hematopoietic cell transplantation. Journal of Immunology (Baltimore, Md. : 1950). 183: 7196-203. PMID 19890041 DOI: 10.4049/Jimmunol.0900159  0.436
2009 Gyurkocza B, Cao TM, Storb RF, Lange T, Leisenring W, Franke GN, Sorror M, Hoppe R, Maloney DG, Negrin RS, Shizuru JA, Sandmaier BM. Salvage allogeneic hematopoietic cell transplantation with fludarabine and low-dose total body irradiation after rejection of first allografts. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. 15: 1314-22. PMID 19747640 DOI: 10.1016/J.Bbmt.2009.06.011  0.53
2009 Cao TM, Lazzeroni LC, Tsai S, Pang WW, Kao A, Camp NJ, Thomas A, Shizuru JA. Identification of a major susceptibility locus for lethal graft-versus-host disease in MHC-matched mice. Journal of Immunology (Baltimore, Md. : 1950). 183: 462-9. PMID 19525392 DOI: 10.4049/Jimmunol.0900454  0.741
2009 Kohrt HE, Turnbull BB, Heydari K, Shizuru JA, Laport GG, Miklos DB, Johnston LJ, Arai S, Weng WK, Hoppe RT, Lavori PW, Blume KG, Negrin RS, Strober S, Lowsky R. TLI and ATG conditioning with low risk of graft-versus-host disease retains antitumor reactions after allogeneic hematopoietic cell transplantation from related and unrelated donors. Blood. 114: 1099-109. PMID 19423725 DOI: 10.1182/Blood-2009-03-211441  0.559
2009 Cao TM, Thomas A, Wang Y, Tsai S, Logronio K, Shizuru JA. A chromosome 16 quantitative trait locus regulates allogeneic bone marrow engraftment in nonmyeloablated mice. Blood. 114: 202-10. PMID 19417206 DOI: 10.1182/Blood-2009-03-208801  0.424
2009 Tsao GJ, Allen JA, Logronio KA, Lazzeroni LC, Shizuru JA. Purified hematopoietic stem cell allografts reconstitute immunity superior to bone marrow. Proceedings of the National Academy of Sciences of the United States of America. 106: 3288-93. PMID 19223585 DOI: 10.1073/Pnas.0813335106  0.584
2009 Rotta M, Storer BE, Sahebi F, Shizuru JA, Bruno B, Lange T, Agura ED, McSweeney PA, Pulsipher MA, Hari P, Maziarz RT, Chauncey TR, Appelbaum FR, Sorror ML, Bensinger W, et al. Long-term outcome of patients with multiple myeloma after autologous hematopoietic cell transplantation and nonmyeloablative allografting. Blood. 113: 3383-91. PMID 19015394 DOI: 10.1182/Blood-2008-07-170746  0.465
2009 Mueller AM, Miklos D, Shizuru J. Modeling Chronic Graft-Versus-Host-Disease: A New MHC-Matched Model of Late-Onset Scleroderma After Low-Dose Conditioning and Hematopoietic Cell Transplantation That Affects Only Male Recipients of Female Grafts. Blood. 114: 3560-3560. DOI: 10.1182/Blood.V114.22.3560.3560  0.53
2009 Tran P, Mueller AM, Shizuru J. The Liver Can Host Donor Hematopoiesis and Maintains a Strong Population of Innate Immune Cells That Contributes to Host Protection After Transplantation of Purified Hematopoietic Stem Cells. Blood. 114: 3545-3545. DOI: 10.1182/Blood.V114.22.3545.3545  0.554
2009 Mueller AM, Florek M, Shizuru J. Engraftment Failure After Non-Myeloablative Hematopoietic Stem Cell Transplantation: Donor CD4 Cells Interfere with Residual Host Cells and Can Trigger Rejection of the Graft. Blood. 114: 3528-3528. DOI: 10.1182/Blood.V114.22.3528.3528  0.619
2009 Rotta M, Storer BE, Lange T, Pulsipher M, Shizuru J, Bruno B, McSweeney PA, Agura E, Chauncey T, Appelbaum FR, Bensinger W, Sandmaier BM, Storb RF, Georges GE, Maloney DG. Nonmyeloablative Allogeneic HCT From Unrelated Donors for Multiple Myeloma (MM). Blood. 114: 3391-3391. DOI: 10.1182/Blood.V114.22.3391.3391  0.417
2009 Chen GL, Arai S, Flowers ME, Otani J, Cheng EC, McMillan A, Weng W, Shizuru J, Johnston L, Miklos D. A Dose Escalation Trial of Imatinib for Steroid Dependent Chronic Graft-Versus-Host Disease with Anti-PDGFRA Antibody Analysis. Blood. 114: 3304-3304. DOI: 10.1182/Blood.V114.22.3304.3304  0.313
2009 Ram R, Storb RF, Maloney DG, Sandmaier BM, Maris M, Shizuru J, Chauncey T, Langston AA, Georges GE. Reduced Intensity Conditioning with Allogeneic Hematopoietic Cell Transplantation for the Treatment of High-Risk Acute Lymphoblastic Leukemia. Blood. 114: 1210-1210. DOI: 10.1182/Blood.V114.22.1210.1210  0.384
2008 Weissman IL, Shizuru JA. The origins of the identification and isolation of hematopoietic stem cells, and their capability to induce donor-specific transplantation tolerance and treat autoimmune diseases Blood. 112: 3543-3553. PMID 18948588 DOI: 10.1182/Blood-2008-08-078220  0.629
2008 Sorror ML, Storer BE, Sandmaier BM, Maris M, Shizuru J, Maziarz R, Agura E, Chauncey TR, Pulsipher MA, McSweeney PA, Wade JC, Bruno B, Langston A, Radich J, Niederwieser D, et al. Five-year follow-up of patients with advanced chronic lymphocytic leukemia treated with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 4912-20. PMID 18794548 DOI: 10.1200/Jco.2007.15.4757  0.531
2008 Rezvani AR, Norasetthada L, Gooley T, Sorror M, Bouvier ME, Sahebi F, Agura E, Chauncey T, Maziarz RT, Maris M, Shizuru J, Bruno B, Bredeson C, Lange T, Yeager A, et al. Non-myeloablative allogeneic haematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: a multicentre experience. British Journal of Haematology. 143: 395-403. PMID 18759762 DOI: 10.1111/J.1365-2141.2008.07365.X  0.467
2008 Streetz KL, Doyonnas R, Grimm D, Jenkins DD, Fuess S, Perryman S, Lin J, Trautwein C, Shizuru J, Blau H, Sylvester KG, Kay MA. Hepatic parenchymal replacement in mice by transplanted allogeneic hepatocytes is facilitated by bone marrow transplantation and mediated by CD4 cells. Hepatology (Baltimore, Md.). 47: 706-18. PMID 18220289 DOI: 10.1002/Hep.22012  0.566
2008 Scandling JD, Busque S, Dejbakhsh-Jones S, Benike C, Millan MT, Shizuru JA, Hoppe RT, Lowsky R, Engleman EG, Strober S. Tolerance and chimerism after renal and hematopoietic-cell transplantation. The New England Journal of Medicine. 358: 362-8. PMID 18216356 DOI: 10.1056/Nejmoa074191  0.567
2008 Rezvani AR, Storer B, Maris M, Sorror ML, Agura E, Maziarz RT, Wade JC, Chauncey T, Forman SJ, Lange T, Shizuru J, Langston A, Pulsipher MA, Sandmaier BM, Storb R, et al. Nonmyeloablative allogeneic hematopoietic cell transplantation in relapsed, refractory, and transformed indolent non-Hodgkin's lymphoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 211-7. PMID 18056679 DOI: 10.1200/Jco.2007.11.5477  0.479
2008 Arai S, Sahaf B, Jones C, Zhender J, Lowsky R, Strober S, Shizuru J, Negrin R, Johnston L, Laport G, Schaenman J, Brown J, Weng W, Letsinger R, Wong R, et al. Prophylactic Rituximab after Reduced Intensity Conditioning Transplantation Results in Low Chronic Gvhd Blood. 112: 466-466. DOI: 10.1182/Blood.V112.11.466.466  0.519
2008 Benjamin JE, Laport GG, Johnston LJ, Arai S, Weng W, Shizuru JA, Miklos DB, Wong RM, Elder LV, Blume KG, Negrin RS, Lowsky R. Long-Term Outcomes of Myeloablative Conditioning and Matched-Related Donor Hematopoietic Cell Transplantation for Patients with High-Risk and Advanced-Stage Hematolymphoid Malignancies Blood. 112: 4383-4383. DOI: 10.1182/Blood.V112.11.4383.4383  0.491
2008 Johnston L, Florek M, Armstrong R, McCune JS, Arai S, Laport G, Lowsky R, Miklos D, Shizuru J, Weng W, Sheehan K, Lavori P, Negrin R. Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis in Myeloablative, Matched Related Donor Hematopoietic Cell Transplantation Blood. 112: 4348-4348. DOI: 10.1182/Blood.V112.11.4348.4348  0.466
2008 Mueller AM, Allen JA, Miklos D, Berry K, Shizuru J. Composition and Persistence of Donor Cell Infiltrates in Host Target Organs Instigate the Development of Chronic Graft-Versus-Host Disease Blood. 112: 3523-3523. DOI: 10.1182/Blood.V112.11.3523.3523  0.515
2008 Kohrt H, Turnbull B, Laport G, Miklos D, Shizuru J, Johnston L, Arai S, Weng WK, Benjamin J, Blume K, Negrin R, Lavori P, Strober S, Lowsky R. Outcomes Following Allogeneic Hematopoietic Cell Transplantation (HCT) Using Non-Myeloablative Conditioning with Total Lymphoid Irradiation (TLI) and Anti-Thymocyte Globulin (ATG) Confirm a Low Incidence of Graft Versus Host Disease (GVHD) with Retained Anti-Tumor Activity Blood. 112: 3310-3310. DOI: 10.1182/Blood.V112.11.3310.3310  0.403
2008 Gyurkocza B, Cao TM, Storb RF, Lange T, Leisenring W, Franke G, Sorror ML, Maloney DG, Shizuru J, Sandmaier BM. Salvage Allogeneic Hematopoietic Cell Transplantation with Fludarabine and Total Body Irradiation (3 or 4 Gy) after Failure of First Allografts. Blood. 112: 3272-3272. DOI: 10.1182/Blood.V112.11.3272.3272  0.48
2008 Arai S, Letsinger R, Johnston L, Laport G, Lowsky R, Miklos D, Shizuru J, Weng W, Wong R, Lavori P, Blume K, Negrin R, Horning S. Phase I/II Trial of a Novel Gemcitabine and Vinorelbine-Containing Conditioning Regimen in Autologous Hemotopoietic Cell Transplantation for High-Risk Recurrent and Refractory Hodgkin Lymphoma. Blood. 112: 2194-2194. DOI: 10.1182/Blood.V112.11.2194.2194  0.389
2008 Lowsky R, Shizuru J, Busque S, Scandling J, Sarwal M, Jones S, Benike C, Hoppe R, Engleman E, Strober S. Chimerism and Tolerance after Combined Human Kidney and Hematopoietic Cell Transplantation Using Conditioning with Total Lymphoid Irradiation and Anti-Thymocyte Globulin. Blood. 112: 2174-2174. DOI: 10.1182/Blood.V112.11.2174.2174  0.596
2008 Sorror ML, Storer B, Sandmaier BM, Maloney DG, Franke G, Shizuru J, Chauncey T, Agura E, Maziarz RT, Sahebi F, Langston AA, Wade JC, Maris M, Bruno B, Yeager AM, et al. Allogeneic Hematopoietic Cell Transplantation (HCT) after Nonmyeloablative Conditioning for Patients (pts) Aged ≥60 Years. Blood. 112: 2162-2162. DOI: 10.1182/Blood.V112.11.2162.2162  0.374
2008 Sorror ML, Storer B, Sandmaier BM, Maris M, Chauncey T, Maziarz RT, Pulsipher M, Shizuru J, Niederwieser D, Agura E, Wade JC, Langston AA, Storb RF, Maloney DG. Sustained Graft-Versus-Lymphoma Effect among Patients (pts) with Mantle Cell Lymphoma (MCL) Given Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation (HCT). Blood. 112: 2147-2147. DOI: 10.1182/Blood.V112.11.2147.2147  0.375
2008 Gyurkocza B, Storb RF, Storer B, Chauncey T, Niederwieser D, Shizuru J, Langston A, Pulsipher M, Bredeson C, Maziarz RT, Bruno B, Petersen F, Maris M, Agura E, Yeager AM, et al. Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation in Patients with De Novo and Secondary Acute Myeloid Leukemia Blood. 112: 149-149. DOI: 10.1182/Blood.V112.11.149.149  0.395
2008 Rotta M, Storer B, Sahebi F, Shizuru JA, Bruno B, Lange T, McSweeney PA, Pulsipher M, Hari P, Maziarz RT, Agura E, Chauncey T, Appelbaum F, Bensinger W, Sandmaier B, et al. Tandem Auto/AlloHCT for Newly Diagnosed Multiple Myeloma (MM) Patients. Blood. 112: 1130-1130. DOI: 10.1182/Blood.V112.11.1130.1130  0.368
2008 Busque S, Scandling J, Shizuru J, Sarwall M, Jones S, Benike C, Engleman E, Lowsky R, Hoppe R, Strober S. INFLUENCE OF CHIMERISM ON TOLERANCE AFTER COMBINED HUMAN KIDNEY AND HEMATOPOIETIC CELL TRANSPLANTATION Transplantation. 86: 228. DOI: 10.1097/01.Tp.0000332175.65116.64  0.554
2008 Mueller A, Allen J, Miklos D, Tung J, Shizuru J. 395: Impact of Donor T Cells on B Cell Development after Hematopoietic Cell Transplantation: Lessons from B Cell Deficient Mice Biology of Blood and Marrow Transplantation. 14: 143-144. DOI: 10.1016/j.bbmt.2007.12.405  0.423
2007 Baron F, Sandmaier BM, Storer BE, Maris MB, Langston AA, Lange T, Petersdorf E, Bethge W, Maziarz RT, McSweeney PA, Pulsipher MA, Wade JC, Chauncey TR, Shizuru JA, Sorror ML, et al. Extended mycophenolate mofetil and shortened cyclosporine failed to reduce graft-versus-host disease after unrelated hematopoietic cell transplantation with nonmyeloablative conditioning. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. 13: 1041-8. PMID 17697966 DOI: 10.1016/J.Bbmt.2007.05.011  0.453
2007 Georges GE, Maris MB, Maloney DG, Sandmaier BM, Sorror ML, Shizuru JA, Lange T, Agura ED, Bruno B, McSweeney PA, Pulsipher MA, Chauncey TR, Mielcarek M, Storer BE, Storb R. Nonmyeloablative unrelated donor hematopoietic cell transplantation to treat patients with poor-risk, relapsed, or refractory multiple myeloma. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. 13: 423-32. PMID 17287157 DOI: 10.1016/J.Bbmt.2006.11.011  0.551
2007 Arai S, Sheehan K, Moore S, Laport G, Johnston L, Lowsky R, Miklos D, Goldstein K, Weng W, Shizuru J, Horning S, Negrin R. Autologous Cytokine-Induced Killer Cells as Post-Transplant Cellular Immunotherapy. Blood. 110: 580-580. DOI: 10.1182/Blood.V110.11.580.580  0.544
2007 Tsao GJ, Allen JA, Logronio K, Lazzeroni LC, Shizuru JA. Pure Hematopoietic Stem Cells Reconstitute Immunity in Allogeneic Hosts Superior to Bone Marrow: Immunosuppression by Subclinical Graft-Versus-Host Disease. Blood. 110: 4869-4869. DOI: 10.1182/Blood.V110.11.4869.4869  0.593
2007 Mueller AM, Allen JA, Miklos D, Shizuru JA. Donor T Cells from B Cell Deficient Mice Inhibit B Cell Development in Normal Recipients after Hematopoietic Cell Transplantation. Blood. 110: 3265-3265. DOI: 10.1182/blood.v110.11.3265.3265  0.476
2007 Lee L, Burge M, Ho P, Sobel R, Shizuru J. Purified MHC-Matched Hematopoietic Stem Cell Transplantation Following Total Lymphoid Irradiation and Anti-Thymocyte Globulin (TLI+ATG) Blocks EAE Pathogenesis. Blood. 110: 3259-3259. DOI: 10.1182/Blood.V110.11.3259.3259  0.595
2007 Mueller AM, Allen JA, Miklos D, Shizuru JA. Comparison of Three Minor-Mismatched Mouse Models of Chronic Graft Versus Host Disease. Blood. 110: 3237-3237. DOI: 10.1182/blood.v110.11.3237.3237  0.476
2007 Rotta M, Storer B, Sahebi F, Shizuru JA, Benedetto B, Lange T, McSweeney PA, Pulsipher MA, Hari P, Maziarz RT, Agura ED, Chauncey T, Appelbaum FR, Sorror ML, Bensinger W, et al. Long-Term Outcome of Autologous Followed by Nonmyeloablative Allografting from HLA-Identical Sibling for Multiple Myeloma (MM). Blood. 110: 3029-3029. DOI: 10.1182/Blood.V110.11.3029.3029  0.404
2007 Sorror ML, Storer B, Sandmaier BM, Maris MB, Shizuru J, Leis J, Agura E, Chauncey T, Pulsipher M, McSweeney P, Wade J, Bruno B, Langston A, Radich J, Niederwieser D, et al. Long-Term Follow Up of Patients (pts) with High-Risk Chronic Lymphocytic Leukemia (CLL) Given Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation (HCT). Blood. 110: 1662-1662. DOI: 10.1182/Blood.V110.11.1662.1662  0.352
2007 Lee L, Burge M, Landa R, Sobels R, Ho P, Shizuru J. Purified MHC-matched Hematopoietic Stem Cell Transplantation Following Total Lymphoid Irradiation and Anti-thymocyte Globulin (TLI+ATG) Blocks EAE Pathogenesis Clinical Immunology. 123: S104. DOI: 10.1016/J.Clim.2007.03.475  0.608
2007 Sorror M, Storer B, Sandmaier B, Maris M, Shizuru J, Niederwieser D, Agura E, Chauncey T, Maziarz R, Pulsipher M, McSweeney P, Wade J, Bruno B, Langston A, Blume K, et al. 368: Longer follow up of patients (pts) with advanced chronic lymphocytic leukemia (CLL) treated with nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation (HCT) Biology of Blood and Marrow Transplantation. 13: 133-134. DOI: 10.1016/J.BBMT.2006.12.373  0.447
2007 Arai S, Sahaf B, Jones C, Zehnder J, Lowsky R, Strober S, Shizuru J, Negrin R, Johnston L, Laport G, Goldstein K, Brown J, Elder L, Tierney K, Lavori P, et al. 283: Rituximab infusion two months after total lymphoid irradiation-antithymocyte globulin (TLI-ATG) nonmyeloablative transplantation maintains B-cell disease control with minimal GVHD Biology of Blood and Marrow Transplantation. 13: 103. DOI: 10.1016/J.Bbmt.2006.12.288  0.421
2006 Baron F, Storb R, Storer BE, Maris MB, Niederwieser D, Shizuru JA, Chauncey TR, Bruno B, Forman SJ, McSweeney PA, Maziarz RT, Pulsipher MA, Agura ED, Wade J, Sorror M, et al. Factors associated with outcomes in allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning after failed myeloablative hematopoietic cell transplantation. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 24: 4150-7. PMID 16896000 DOI: 10.1200/Jco.2006.06.9914  0.571
2006 Law LY, Horning SJ, Wong RM, Johnston LJ, Laport GG, Lowsky R, Shizuru JA, Blume KG, Negrin RS, Stockerl-Goldstein KE. High-dose carmustine, etoposide, and cyclophosphamide followed by allogeneic hematopoietic cell transplantation for non-Hodgkin lymphoma. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. 12: 703-11. PMID 16785059 DOI: 10.1016/J.Bbmt.2006.02.009  0.469
2006 Maris MB, Sandmaier BM, Storer BE, Maloney DG, Shizuru JA, Agura E, Kliem C, Pulsipher M, Maziarz RT, McSweeney PA, Wade J, Langston AA, Chauncey TR, Bruno B, Blume KG, et al. Unrelated donor granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cell transplantation after nonmyeloablative conditioning: the effect of postgrafting mycophenolate mofetil dosing. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. 12: 454-65. PMID 16545729 DOI: 10.1016/J.Bbmt.2005.12.030  0.466
2006 Schultz KR, Miklos DB, Fowler D, Cooke K, Shizuru J, Zorn E, Holler E, Ferrara J, Shulman H, Lee SJ, Martin P, Filipovich AH, Flowers ME, Weisdorf D, Couriel D, et al. Toward biomarkers for chronic graft-versus-host disease: National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: III. Biomarker Working Group Report. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. 12: 126-37. PMID 16443511 DOI: 10.1016/J.Bbmt.2005.11.010  0.346
2006 Hegenbart U, Niederwieser D, Sandmaier BM, Maris MB, Shizuru JA, Greinix H, Cordonnier C, Rio B, Gratwohl A, Lange T, Al-Ali H, Storer B, Maloney D, McSweeney P, Chauncey T, et al. Treatment for acute myelogenous leukemia by low-dose, total-body, irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donors. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 24: 444-53. PMID 16344316 DOI: 10.1200/Jco.2005.03.1765  0.526
2006 Lowsky R, Stockerl-Goldstein K, Laport G, Miklos D, Arai S, Shizuru J, Johnston L, Blume K, Negrin R, Strober S. Clinical Outcomes Following Allogeneic Hematopoietic Cell Transplantation (HCT) Using Nonmyeloablative Host Conditioning with Total Lymphoid Irradiation and Anti-Thymocyte Globulin Confirm a Low Incidence of Graft Versus Host Disease (GVHD) and Retained Graft Anti-Tumor Activity. Blood. 108: 603-603. DOI: 10.1182/Blood.V108.11.603.603  0.527
2006 Cao TM, Stockerl-Goldstein KE, Cao PD, Laport GG, Sheehan K, Shizuru JA, Johnston LJ, Negrin RS, Lowsky R. High Dose Therapy and Autologous Hematopoietic Cell Transplantation for Primary Refractory Diffuse Large Cell Non-Hodgkin’s Lymphoma. Blood. 108: 5466-5466. DOI: 10.1182/Blood.V108.11.5466.5466  0.433
2006 Laport GG, Sheehan K, Lowsky R, Shizuru JA, Stockerl-Goldstein K, Johnston LJ, Miklos D, Arai S, Baker J, Negrin RS. Cytokine Induced Killer (CIK) Cells as Post-Transplant Immunotherapy Following Allogeneic Hematopoietic Cell Transplantation. Blood. 108: 412-412. DOI: 10.1182/Blood.V108.11.412.412  0.525
2006 Rezvani AR, Sandmaier BM, Storer B, Maris M, Agura E, Maziarz R, Wade JC, Chauncey T, Forman SJ, Niederwieser DW, Shizuru J, Langston A, Pulsipher M, Storb RF, Maloney DG. Outcomes of c Hematopoietic Stem Cell Transplantation (HCT) after Non-Myeloablative Conditioning in Relapsed, Refractory, or Transformed Indolent Non-Hodgkin Lymphoma (NHL). Blood. 108: 3124-3124. DOI: 10.1182/Blood.V108.11.3124.3124  0.408
2006 Baron F, Sandmaier BM, Storer B, Maris M, Langston A, Niederwieser DW, Petersdorf E, Bethge W, Maziarz RT, McSweeney P, Pulsipher M, Wade JC, Chauncey T, Shizuru J, Woolfrey A, et al. Postgrafting Immunosuppression with Prolonged Mycophenolate Mofetil (MMF) and Truncated Cyclosporine (CSP) Failed To Reduce the Incidence of Graft-Versus-Host Disease (GVHD) after Unrelated Donor Hematopoietic Cell Transplantation (HCT) with Nonmyeloablative Conditioning. Blood. 108: 3119-3119. DOI: 10.1182/Blood.V108.11.3119.3119  0.418
2006 Arai S, Sahaf B, Jones C, Zehnder J, Lowsky R, Strober S, Shizuru J, Negrin R, Johnston L, Laport G, Goldstein K, Brown J(, Miklos D. Rituximab Infusion Two Months after Nonmyeloablative Transplantation Maintains B-Cell Disease Control with Minimal GVHD. Blood. 108: 2907-2907. DOI: 10.1182/Blood.V108.11.2907.2907  0.492
2006 Muchmore M, Burge M, Shizuru J. Durable engraftment of purified allogeneic hematopoietic stem cells following non-myeloablative conditioning Biology of Blood and Marrow Transplantation. 12: 36-37. DOI: 10.1182/Blood.V106.11.2204.2204  0.609
2006 Logronio K, Burge M, Shizuru J. Lack of immune barrier to allogeneic hematopoietic stem cell engraftment in T, B, and NK cell deficient (Rag2γc−/−B6) mice Biology of Blood and Marrow Transplantation. 12: 26. DOI: 10.1182/Blood.V106.11.1269.1269  0.473
2006 FEINSTEIN L, SANDMAIER B, MALONEY D, McSWEENEY PA, MARIS M, FLOWERS C, RADICH J, LITTLE M, NASH RA, CHAUNCEY T, WOOLFREY A, GEORGES G, KIEM H, ZAUCHA JM, BLUME KG, ... SHIZURU J, et al. Nonmyeloablative Hematopoietic Cell Transplantation Annals of the New York Academy of Sciences. 938: 328-339. DOI: 10.1111/J.1749-6632.2001.Tb03601.X  0.558
2006 Streetz K, Doyonnas R, Jenkins D, Perryman S, Lin S, Trautwein C, Shizuru J, Blau H, Sylvester K, Kay M. In vivo selection of liver cells in a model of allogeneic bone-marrow-transplantation Zeitschrift FüR Gastroenterologie. 44. DOI: 10.1055/s-2006-950752  0.388
2006 Streetz K, Doyonnas R, Jenkins D, Perryman S, Fuess S, Lin S, Shizuru J, Blau H, Trautwein C, Sylvester K, Kay M. 75 In vivo selection of primary and bone-marrowderived hepatocytes after allogeneic transplantation in mice Journal of Hepatology. 44: S33. DOI: 10.1016/S0168-8278(06)80076-0  0.364
2006 Georges G, Maris M, Maloney D, Sandmaier B, Sorror M, Shizuru J, Niederwieser D, Agura E, Bruno B, McSweeney P, Pulsipher M, Chauncey T, Storer B, Storb R. Nonmyeloablative unrelated donor (URD) hematopoietic cell transplantation (HCT) for the treatment of patients (PTS) with poor-risk, relapsed or refractory multiple myeloma Biology of Blood and Marrow Transplantation. 12: 19. DOI: 10.1016/j.bbmt.2005.11.061  0.435
2005 Arai S, Negrin R, Blume K, Johnston L, Laport G, Lowsky R, Shizuru J, Stockerl-Goldstein K, Letsinger R, Wong R, Horning S. A phase I trial with extended cohort of gemcitabine and vinorelbine followed by autologous peripheral blood stem cell transplantation for recurrent or refractory Hodgkin's lymphoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 6651. PMID 27944329 DOI: 10.1200/jco.2005.23.16_suppl.6651  0.441
2005 Lowsky R, Takahashi T, Liu YP, Dejbakhsh-Jones S, Grumet FC, Shizuru JA, Laport GG, Stockerl-Goldstein KE, Johnston LJ, Hoppe RT, Bloch DA, Blume KG, Negrin RS, Strober S. Protective conditioning for acute graft-versus-host disease. The New England Journal of Medicine. 353: 1321-31. PMID 16192477 DOI: 10.1056/Nejmoa050642  0.504
2005 Beilhack GF, Landa RR, Masek MA, Shizuru JA. Prevention of type 1 diabetes with major histocompatibility complex-compatible and nonmarrow ablative hematopoietic stem cell transplants. Diabetes. 54: 1770-9. PMID 15919799 DOI: 10.2337/Diabetes.54.6.1770  0.544
2005 Mielcarek M, Burroughs L, Leisenring W, Diaconescu R, Martin PJ, Sandmaier BM, Maloney DG, Maris MB, Chauncey TR, Shizuru JA, Blume KG, Hegenbart U, Niederwieser D, Forman S, Bruno B, et al. Prognostic relevance of 'early-onset' graft-versus-host disease following non-myeloablative haematopoietic cell transplantation. British Journal of Haematology. 129: 381-91. PMID 15842663 DOI: 10.1111/j.1365-2141.2005.05458.x  0.523
2005 Baron F, Maris MB, Storer BE, Sandmaier BM, Stuart MJ, McSweeney PA, Radich JP, Pulsipher MA, Agura ED, Chauncey TR, Maloney DG, Shizuru JA, Storb R. HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with chronic myeloid leukemia. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. 11: 272-9. PMID 15812392 DOI: 10.1016/J.Bbmt.2004.12.326  0.522
2005 Kerbauy FR, Storb R, Hegenbart U, Gooley T, Shizuru J, Al-Ali HK, Radich JP, Maloney DG, Agura E, Bruno B, Epner EM, Chauncey TR, Blume KG, Niederwieser D, Sandmaier BM. Hematopoietic cell transplantation from HLA-identical sibling donors after low-dose radiation-based conditioning for treatment of CML. Leukemia. 19: 990-7. PMID 15800667 DOI: 10.1038/Sj.Leu.2403730  0.456
2005 Cao TM, Wong RM, Sheehan K, Laport GG, Stockerl-Goldstein KE, Johnston LJ, Shizuru JA, Negrin RS, Lowsky R. CD34, CD4, and CD8 cell doses do not influence engraftment, graft-versus-host disease, or survival following myeloablative human leukocyte antigen-identical peripheral blood allografting for hematologic malignancies. Experimental Hematology. 33: 279-85. PMID 15730851 DOI: 10.1016/J.Exphem.2004.12.004  0.561
2005 Shizuru JA, Negrin RS, Weissman IL. Hematopoietic stem and progenitor cells: clinical and preclinical regeneration of the hematolymphoid system. Annual Review of Medicine. 56: 509-38. PMID 15660525 DOI: 10.1146/Annurev.Med.54.101601.152334  0.614
2005 Johnston LJ, Brown J, Shizuru JA, Stockerl-Goldstein KE, Stuart MJ, Blume KG, Negrin RS, Chao NJ. Rapamycin (sirolimus) for treatment of chronic graft-versus-host disease. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. 11: 47-55. PMID 15625544 DOI: 10.1016/J.Bbmt.2004.10.004  0.33
2005 Scheffold C, Scheffold YC, Cao TM, Gworek J, Shizuru JA. Cytokines and cytotoxic pathways in engraftment resistance to purified allogeneic hematopoietic stem cells. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. 11: 1-12. PMID 15625539 DOI: 10.1016/J.Bbmt.2004.10.002  0.55
2005 Cao TM, Shizuru JA, Wong RM, Sheehan K, Laport GG, Stockerl-Goldstein KE, Johnston LJ, Stuart MJ, Grumet FC, Negrin RS, Lowsky R. Engraftment and survival following reduced-intensity allogeneic peripheral blood hematopoietic cell transplantation is affected by CD8+ T-cell dose. Blood. 105: 2300-6. PMID 15572597 DOI: 10.1182/Blood-2004-04-1473  0.531
2005 Lowsky R, Heydari K, Sahaf B, Shizuru J, Laport G, Johnston L, Stockerl-Goldstein K, Arai S, Miklos D, Blume K, Herzenberg L, Negrin R, Strober S. Haploidentical Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation (HCT) Using Total Lymphoid Irradiation (TLI) and Anti-Thymocyte Globulin (ATG) Conditioning Protects Against Acute Graft Versus Host Disease (GVHD). Blood. 106: 2904-2904. DOI: 10.1182/Blood.V106.11.2904.2904  0.48
2005 Georges GE, Maris MB, Maloney DG, Sandmaier BM, Sorror ML, Shizuru JA, Niederwieser DW, Agura ED, Bruno B, McSweeney PA, Pulsipher MA, Chauncey TR, Storer BE, Storb RF. Nonmyeloablative Unrelated Donor (URD) Hematopoietic Cell Transplantation (HCT) for the Treatment of Patients (pts) with Poor-Risk, Relapsed or Refractory Multiple Myeloma. Blood. 106: 2893-2893. DOI: 10.1182/Blood.V106.11.2893.2893  0.384
2005 Muchmore MA, Burge MJ, Shizuru JA. Durable Engraftment of Purified Allogeneic Hematopoietic Stem Cells Following Non-Myeloablative Conditioning. Blood. 106: 2204-2204. DOI: 10.1182/blood.v106.11.2204.2204  0.532
2005 Baron F, Storb R, Storer B, Maloney D, Maris M, Niederwieser D, Shizuru J, Chauncey T, Bruno B, Forman S, McSweeney P, Maziarz R, Pulsipher M, Agura E, Sorror M, et al. Allogeneic Hematopoietic Cell Transplantation (HCT) with Nonmyeloablative Conditioning after Failed Myeloablative HCT: Factors Affecting Outcomes. Blood. 106: 1143-1143. DOI: 10.1182/BLOOD.V106.11.1143.1143  0.332
2005 Maris MB, Sandmaier BM, Storer B, Agura E, Wade J, Maziarz RT, Forman S, Shizuru J, Chauncey T, Kahl C, Langston AA, Niederwieser D, Storb R, Maloney DG. Allogeneic Hematopoietic Cell Transplantation (HCT) after Nonmyeloablative Conditioning for Relapsed or Refractory Follicular Lymphoma. Blood. 106: 1130-1130. DOI: 10.1182/BLOOD.V106.11.1130.1130  0.304
2005 Streetz KL, Doyonnas R, Jenkins DD, Lin S, Shizuru JA, Blau H, Sylvester K, Kay MA. 467. Allogeneic Bone-Marrow Transplantation in Mice Provides Tolerance and Promotes Massive In Vivo Selection of Subsequently Transplanted Hepatocytes Molecular Therapy. 11. DOI: 10.1016/J.Ymthe.2005.07.007  0.562
2004 Strober S, Lowsky RJ, Shizuru JA, Scandling JD, Millan MT. Approaches to transplantation tolerance in humans. Transplantation. 77: 932-6. PMID 15077041 DOI: 10.1097/01.Tp.0000117782.93598.6E  0.477
2004 Horwitz SM, Negrin RS, Blume KG, Breslin S, Stuart MJ, Stockerl-Goldstein KE, Johnston LJ, Wong RM, Shizuru JA, Horning SJ. Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma. Blood. 103: 777-83. PMID 12907446 DOI: 10.1182/Blood-2003-04-1257  0.472
2004 Cao TM, Pang WW, Grumet FC, Lazzeroni LC, Shizuru JA. Genetic Susceptibility Loci for Lethal Graft-Versus-Host Disease in MHC-Identical Mice: Initial Results from a Genome-Wide Scan. Blood. 104: 4986-4986. DOI: 10.1182/Blood.V104.11.4986.4986  0.724
2004 Lowsky R, Takahashi T, Ping Y, Shizuru J, Negrin RS, Strober S. Non-Myeloablative Conditioning of Total Lymphoid Irradiation (TLI) and Anti-Thymocyte Globulin (ATG) Protects Against Acute GVHD Following Allogeneic Hematopoietic Cell Transplantation (HCT) but Retains Anti-Tumor Activity. Blood. 104: 433-433. DOI: 10.1182/Blood.V104.11.433.433  0.574
2004 Georges GE, Maris MB, Sandmaier BM, Shizuru J, Niederwieser DW, Agura E, Bruno B, McSweeney8 PA, Storb RF, Maloney DG. Nonmyeloablative Unrelated Donor Hematopoietic Cell Transplantation (HCT) for Patients (pts) with Poor Risk, Relapsed or Refractory Multiple Myeloma. Blood. 104: 2756-2756. DOI: 10.1182/Blood.V104.11.2756.2756  0.376
2004 Kerbauy FR, Lange T, Gooley T, Shizuru J, Radich J, Maloney DG, Agura E, Bruno B, Epner E, Chauncey T, Blume K, Storb R, Niederwieser D, Sandmaier BM. Non-Myeloablative Allografting from HLA-Identical Sibling Donors for Treatment of CML. Blood. 104: 2316-2316. DOI: 10.1182/Blood.V104.11.2316.2316  0.494
2004 Cao TM, Shizuru JA, Wong RM, Sheehan K, Laport GG, Stockerl-Goldstein KE, Johnston LJ, Stuart MJ, Brown JM, Grumet FC, Negrin RS, Lowsky R. Engraftment and Survival Following Non-Myeloablative Allogeneic Peripheral Blood Hematopoietic Cell Transplantation for Malignant Diseases Is Affected by CD8+ T-Cell Dose. Blood. 104: 183-183. DOI: 10.1182/Blood.V104.11.183.183  0.505
2004 Maris MB, Sandmaier BM, Storer B, Shizuru J, Maloney D, Agura E, Niederwieser D, Pulsipher M, Maziarz RT, McSweeney P, Wade J, Langston A, Chauncey T, Bruno B, Woolfrey A, et al. Unrelated Donor Peripheral Blood Stem Cell (PBSC) Transplantation Using Nonmyeloablative Conditioning and Mycophenolate Mofetil (MMF) TID Results in High Engraftment Rates. Blood. 104: 1818-1818. DOI: 10.1182/BLOOD.V104.11.1818.1818  0.415
2003 Cao TM, Lo B, Ranheim EA, Grumet FC, Shizuru JA. Variable hematopoietic graft rejection and graft-versus-host disease in MHC-matched strains of mice. Proceedings of the National Academy of Sciences of the United States of America. 100: 11571-6. PMID 14504392 DOI: 10.1073/Pnas.2035077100  0.472
2003 Arber C, BitMansour A, Sparer TE, Higgins JP, Mocarski ES, Weissman IL, Shizuru JA, Brown JM. Common lymphoid progenitors rapidly engraft and protect against lethal murine cytomegalovirus infection after hematopoietic stem cell transplantation. Blood. 102: 421-8. PMID 12663447 DOI: 10.1182/Blood-2002-12-3834  0.684
2003 Kondo M, Wagers AJ, Manz MG, Prohaska SS, Scherer DC, Beilhack GF, Shizuru JA, Weissman IL. Biology of hematopoietic stem cells and progenitors: implications for clinical application. Annual Review of Immunology. 21: 759-806. PMID 12615892 DOI: 10.1146/Annurev.Immunol.21.120601.141007  0.704
2003 Shilling HG, McQueen KL, Cheng NW, Shizuru JA, Negrin RS, Parham P. Reconstitution of NK cell receptor repertoire following HLA-matched hematopoietic cell transplantation. Blood. 101: 3730-40. PMID 12511415 DOI: 10.1182/Blood-2002-08-2568  0.565
2003 Beilhack GF, Scheffold YC, Weissman IL, Taylor C, Jerabek L, Burge MJ, Masek MA, Shizuru JA. Purified allogeneic hematopoietic stem cell transplantation blocks diabetes pathogenesis in NOD mice. Diabetes. 52: 59-68. PMID 12502494 DOI: 10.2337/Diabetes.52.1.59  0.685
2003 Niederwieser D, Maris M, Shizuru JA, Petersdorf E, Hegenbart U, Sandmaier BM, Maloney DG, Storer B, Lange T, Chauncey T, Deininger M, Pönisch W, Anasetti C, Woolfrey A, Little MT, et al. Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases. Blood. 101: 1620-9. PMID 12393457 DOI: 10.1182/Blood-2002-05-1340  0.502
2002 Maloney DG, Sandmaier BM, Mackinnon S, Shizuru JA. Non-myeloablative transplantation. Hematology. American Society of Hematology. Education Program. 392-421. PMID 12446434 DOI: 10.1182/Asheducation-2002.1.392  0.567
2002 Georges GE, Maris M, Sandmaier BM, Malone DG, Feinstein L, Niederweiser D, Shizuru JA, McSweeney PA, Chauncey TR, Agura E, Little MT, Sahebi F, Hegenbart U, Pulsipher MA, Bruno B, et al. Related and unrelated nonmyeloablative hematopoietic stem cell transplantation for malignant diseases. International Journal of Hematology. 76: 184-9. PMID 12430851 DOI: 10.1007/Bf03165242  0.516
2002 Higuchi M, Zeng D, Shizuru J, Gworek J, Dejbakhsh-Jones S, Taniguchi M, Strober S. Immune tolerance to combined organ and bone marrow transplants after fractionated lymphoid irradiation involves regulatory NK T cells and clonal deletion. Journal of Immunology (Baltimore, Md. : 1950). 169: 5564-70. PMID 12421933 DOI: 10.4049/Jimmunol.169.10.5564  0.559
2002 Millan MT, Shizuru JA, Hoffmann P, Dejbakhsh-Jones S, Scandling JD, Grumet FC, Tan JC, Salvatierra O, Hoppe RT, Strober S. Mixed chimerism and immunosuppressive drug withdrawal after HLA-mismatched kidney and hematopoietic progenitor transplantation. Transplantation. 73: 1386-91. PMID 12023614 DOI: 10.1097/00007890-200205150-00005  0.558
2002 Auffermann-Gretzinger S, Lossos IS, Vayntrub TA, Leong W, Grumet FC, Blume KG, Stockerl-Goldstein KE, Levy R, Shizuru JA. Rapid establishment of dendritic cell chimerism in allogeneic hematopoietic cell transplant recipients. Blood. 99: 1442-8. PMID 11830498 DOI: 10.1182/Blood.V99.4.1442  0.579
2001 Stuart MJ, Chao NS, Horning SJ, Wong RM, Negrin RS, Johnston LJ, Shizuru JA, Long GD, Blume KG, Stockerl-Goldstein KE. Efficacy and toxicity of a CCNU-containing high-dose chemotherapy regimen followed by autologous hematopoietic cell transplantation in relapsed or refractory Hodgkin's disease Biology of Blood and Marrow Transplantation. 7: 552-560. PMID 11760087 DOI: 10.1016/S1083-8791(01)70015-8  0.383
2001 Verneris MR, Ito M, Baker J, Arshi A, Negrin RS, Shizuru JA. Engineering hematopoietic grafts: purified allogeneic hematopoietic stem cells plus expanded CD8+ NK-T cells in the treatment of lymphoma. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. 7: 532-42. PMID 11760085 DOI: 10.1016/S1083-8791(01)70014-6  0.578
2001 Maris M, Sandmaier BM, Maloney DG, McSweeney PA, Woolfrey A, Chauncey T, Shizuru J, Niederwieser D, Blume KG, Forman S, Storb R. Non-myeloablative hematopoietic stem cell transplantation. Transfusion Clinique Et Biologique : Journal De La Societe Francaise De Transfusion Sanguine. 8: 231-4. PMID 11499966 DOI: 10.1016/S1246-7820(01)00137-9  0.614
2001 Brown JM, Weissman IL, Shizuru JA. Immunity to infections following hematopoietic cell transplantation. Current Opinion in Immunology. 13: 451-7. PMID 11498301 DOI: 10.1016/S0952-7915(00)00240-5  0.673
2001 Maris M, Woolfrey A, McSweeney PA, Sandmaier BM, Nash RA, Georges G, Maloney DG, Molina A, Chauncey T, Yu C, Zaucha JM, Blume KG, Shizuru J, Niederwieser D, Storb R. Nonmyeloablative hematopoietic stem cell transplantation: transplantation for the 21st century. Frontiers in Bioscience : a Journal and Virtual Library. 6: G13-6. PMID 11487474 DOI: 10.2741/MARIS  0.541
2001 Cao TM, Horning S, Negrin RS, Hu WW, Johnston LJ, Taylor TL, Shizuru JA, Hoppe RT, Brown BW, Blume KG, Stockerl-Goldstein KE. High-dose therapy and autologous hematopoietic-cell transplantation for follicular lymphoma beyond first remission: the Stanford University experience. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. 7: 294-301. PMID 11400952 DOI: 10.1053/Bbmt.2001.V7.Pm11400952  0.413
2001 McSweeney PA, Niederwieser D, Shizuru JA, Sandmaier BM, Molina AJ, Maloney DG, Chauncey TR, Gooley TA, Hegenbart U, Nash RA, Radich J, Wagner JL, Minor S, Appelbaum FR, Bensinger WI, et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood. 97: 3390-400. PMID 11369628 DOI: 10.1182/Blood.V97.11.3390  0.54
2001 Baker J, Verneris MR, Ito M, Shizuru JA, Negrin RS. Expansion of cytolytic CD8(+) natural killer T cells with limited capacity for graft-versus-host disease induction due to interferon gamma production. Blood. 97: 2923-31. PMID 11342413 DOI: 10.1182/Blood.V97.10.2923  0.488
2001 Lagasse E, Shizuru JA, Uchida N, Tsukamoto A, Weissman IL. Toward regenerative medicine. Immunity. 14: 425-36. PMID 11336688 DOI: 10.1016/S1074-7613(01)00123-6  0.809
2001 Storb R, McSweeney PA, Sandmaier BM, Nash RA, Georges G, Maloney DG, Molina A, Chauncey T, Yu C, Zaucha JM, Blume KG, Shizuru J, Niederwieser D. Allogeneic hematopoietic stem cell transplantation: from the nuclear age into the twenty-first century. Transplantation Proceedings. 32: 2548-9. PMID 11120287 DOI: 10.1016/S0041-1345(00)01785-1  0.554
2000 Shizuru JA, Weissman IL, Kernoff R, Masek M, Scheffold YC. Purified hematopoietic stem cell grafts induce tolerance to alloantigens and can mediate positive and negative T cell selection. Proceedings of the National Academy of Sciences of the United States of America. 97: 9555-60. PMID 10920206 DOI: 10.1073/Pnas.170279297  0.661
2000 Cao TM, Negrin RS, Stockerl-Goldstein KE, Johnston LJ, Shizuru JA, Taylor TL, Rizk NW, Wong RM, Blume KG, Hu WW. Pulmonary toxicity syndrome in breast cancer patients undergoing BCNU-containing high-dose chemotherapy and autologous hematopoietic cell transplantation. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. 6: 387-94. PMID 10917574 DOI: 10.1016/S1083-8791(00)70015-2  0.321
2000 Negrin RS, Atkinson K, Leemhuis T, Hanania E, Juttner C, Tierney K, Hu WW, Johnston LJ, Shizuru JA, Stockerl-Goldstein KE, Blume KG, Weisswan IL, Bower S, Baynes R, Dansey R, et al. Transplantation of Highly Purified CD34+Thy-l+ Hematopoietic Stem Cells in Patients with Metastatic Breast Cancer Biology of Blood and Marrow Transplantation. 6: 262-271. PMID 10871151 DOI: 10.1016/S1083-8791(00)70008-5  0.447
2000 Coghlin Dickson TM, Wong RM, Negrin RS, Shizuru JA, Johnston LJ, Hu WW, Blume KG, Stockerl-Goldstein KE. Effect of oral glutamine supplementation during bone marrow transplantation Journal of Parenteral and Enteral Nutrition. 24: 61-66. PMID 10772184 DOI: 10.1177/014860710002400261  0.549
2000 Hu WW, Negrin RS, Stockerl-Goldstein K, Johnston LJ, Shizuru JA, Wong RM, Chao NJ, Long GD, Feiner RH, Blume KG. Four-Cycle High-Dose Therapy With Hematopoietic Support for Metastatic Breast Cancer: No Improvement in Outcomes Compared With Single-Course High-Dose Therapy Biology of Blood and Marrow Transplantation. 6: 58-69. PMID 10708000 DOI: 10.1016/S1083-8791(00)70053-X  0.323
2000 Sandmaier B, Maloney D, McSweeney P, Niederwieser D, Shizuru J, Chauncey T, Gooley T, Molina A, Radich J, Blume K, Storb R. Nonmyeloablative conditioning for stem cell allografts with low-dose tbi Experimental Hematology. 28: 60. DOI: 10.1016/S0301-472X(00)00276-9  0.348
1999 Akashi K, Kondo M, Cheshier S, Shizuru J, Gandy K, Domen J, Mebius R, Traver D, Weissman IL. Lymphoid development from stem cells and the common lymphocyte progenitors. Cold Spring Harbor Symposia On Quantitative Biology. 64: 1-12. PMID 11232274 DOI: 10.1101/Sqb.1999.64.1  0.781
1999 Ito M, Shizuru JA. Graft-vs.-lymphoma effect in an allogeneic hematopoietic stem cell transplantation model. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. 5: 357-68. PMID 10595813 DOI: 10.1016/S1083-8791(99)70012-1  0.627
1999 Dickson TM, Kusnierz-Glaz CR, Blume KG, Negrin RS, Hu WW, Shizuru JA, Johnston LL, Wong RM, Stockerl-Goldstein KE. Impact of admission body weight and chemotherapy dose adjustment on the outcome of autologous bone marrow transplantation. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. 5: 299-305. PMID 10534060 DOI: 10.1016/S1083-8791(99)70005-4  0.312
1999 Weissman IL, Shizuru JA. Immune reconstitution. The New England Journal of Medicine. 341: 1227-9. PMID 10519902 DOI: 10.1056/NEJM199910143411610  0.313
1997 Aguila HL, Akashi K, Domen J, Gandy KL, Lagasse E, Mebius RE, Morrison SJ, Shizuru J, Strober S, Uchida N, Wright DE, Weissman IL. From stem cells to lymphocytes: biology and transplantation. Immunological Reviews. 157: 13-40. PMID 9255619 DOI: 10.1111/J.1600-065X.1997.Tb00971.X  0.849
1996 Shizuru JA, Jerabek L, Edwards CT, Weissman IL. Transplantation of purified hematopoietic stem cells: requirements for overcoming the barriers of allogeneic engraftment. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. 2: 3-14. PMID 9078349  0.679
1994 Lee MS, Wogensen L, Shizuru J, Oldstone MB, Sarvetnick N. Pancreatic islet production of murine interleukin-10 does not inhibit immune-mediated tissue destruction. The Journal of Clinical Investigation. 93: 1332-8. PMID 8132775 DOI: 10.1172/Jci117092  0.332
1993 Chen RH, Ivens KW, Alpert S, Billingham ME, Fathman CG, Flavin TF, Shizuru JA, Starnes VA, Weissman IL, Griffiths GM. The use of granzyme A as a marker of heart transplant rejection in cyclosporine or anti-CD4 monoclonal antibody-treated rats. Transplantation. 55: 146-53. PMID 8420039  0.691
1993 Shizuru JA, Fathman CG. Anti-CD4 antibodies in diabetes Immunology Series. 59: 237-252. PMID 8096401  0.494
1993 Hänninen A, Taylor C, Streeter PR, Stark LS, Sarte JM, Shizuru JA, Simell O, Michie SA. Vascular addressins are induced on islet vessels during insulitis in nonobese diabetic mice and are involved in lymphoid cell binding to islet endothelium. The Journal of Clinical Investigation. 92: 2509-15. PMID 7693764 DOI: 10.1172/Jci116859  0.311
1992 Shizuru JA, Alters SE, Fathman CG. Anti-CD4 monoclonal antibodies in therapy: Creation of nonclassical tolerance in the adult Immunological Reviews. 105-130. PMID 1361179 DOI: 10.1111/J.1600-065X.1992.Tb01421.X  0.605
1991 Alters SE, Shizuru JA, Ackerman J, Grossman D, Seydel KB, Fathman CG. Anti-CD4 mediates clonal anergy during transplantation tolerance induction Journal of Experimental Medicine. 173: 491-494. PMID 1899105 DOI: 10.1084/Jem.173.2.491  0.674
1991 Seydel K, Shizuru J, Grossman D, Wu A, Alters S, Fathman CG. Anti-CD8 abrogates effect of anti-CD4-mediated islet allograft survival in rat model Diabetes. 40: 1430-1434. PMID 1834499 DOI: 10.2337/Diab.40.11.1430  0.662
1991 Shizuru JA, Taylor-Edwards C, Livingstone A, Fathman CG. Genetic dissection of T cell receptor Vβ gene requirements for spontaneous murine diabetes Journal of Experimental Medicine. 174: 633-638. PMID 1831491 DOI: 10.1084/Jem.174.3.633  0.541
1991 Livingstone A, Edwards CT, Shizuru JA, Fathman CG. Genetic analysis of diabetes in the nonobese diabetic mouse. I. MHC and T cell receptor β gene expression Journal of Immunology. 146: 529-534. PMID 1824775  0.452
1990 Sarvetnick N, Shizuru J, Liggitt D, Martin L, McIntyre B, Gregory A, Parslow T, Stewart T. Loss of pancreatic islet tolerance induced by beta-cell expression of interferon-gamma. Nature. 346: 844-7. PMID 2118234 DOI: 10.1038/346844A0  0.314
1990 Flavin T, Shizuru J, Seydel K, Wu A, Fujimoto N, Hoyt EG, Ivens K, Billingham M, Fathman CG, Starnes VA. Selective T-cell depletion with Ox-38 anti-CD4 monoclonal antibody prevents cardiac allograft rejection in rats Journal of Heart Transplantation. 9: 482-488. PMID 1977898  0.634
1990 Shizuru JA, Seydel KB, Flavin TF, Wu AP, Kong CC, Hoyt EG, Fujimoto N, Billingham ME, Starnes VA, Fathman CG. Induction of donor-specific unresponsiveness to cardiac allografts in rats by pretransplant anti-004 monoclonal antibody therapy Transplantation. 50: 366-373. PMID 1976282  0.597
1989 Trager DK, Banks BA, Rosenbaum GE, Holm BI, Shizuru JA, Strober S, Fathman CG. Cardiac allograft prolongation in mice treated with combined posttransplantation total-lymphoid irradiation and anti-L3T4 antibody therapy. Transplantation. 47: 587-91. PMID 2523098  0.561
1988 Shizuru JA, Taylor-Edwards C, Banks BA, Gregory AK, Fathman CG. Immunotherapy of the nonobese diabetic mouse: treatment with an antibody to T-helper lymphocytes. Science (New York, N.Y.). 240: 659-62. PMID 2966437 DOI: 10.1126/Science.2966437  0.55
1987 Shizuru JA, Gregory AK, Chao CTB, Fathman CG. Islet allograft survival after a single course of treatment of recipient with antibody to L3T4 Science. 237: 278-280. PMID 2955518 DOI: 10.1126/Science.2955518  0.683
1986 Shizuru JA, Ramakrishnan S, Hunt T, Merrell RG, Fathman CG. Inhibition of rat mixed lymphocyte pancreatic islet cultures with anti-Ia immunotoxin Transplantation. 42: 660-666. PMID 2947362  0.622
1985 Shizuru J, Trager D, Merrell RC. Structure, function, and immune properties of reassociated islet cells. Diabetes. 34: 898-903. PMID 3161769 DOI: 10.2337/Diab.34.9.898  0.563
Show low-probability matches.